{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T03:22:29Z","timestamp":1791516149087,"version":"4.3.4"},"reference-count":423,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"vor","delay-in-days":1371,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["pharmrev.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Reviews"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1124\/pharmrev.120.000072","type":"journal-article","created":{"date-parts":[[2021,3,9]],"date-time":"2021-03-09T13:30:26Z","timestamp":1615296626000},"page":"792-827","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":207,"title":["Therapeutic Targeting of the Complement System: From Rare Diseases to Pandemics"],"prefix":"10.1016","volume":"73","author":[{"given":"Peter","family":"Garred","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea J.","family":"Tenner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5785-802X","authenticated-orcid":false,"given":"Tom E.","family":"Mollnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/pharmrev.120.000072_bib1","doi-asserted-by":"crossref","first-page":"5442","DOI":"10.4049\/jimmunol.1202339","article-title":"Local complement-targeted intervention in periodontitis: proof-of-concept using a C5a receptor (CD88) antagonist","volume":"189","author":"Abe","year":"2012","journal-title":"J Immunol"},{"key":"10.1124\/pharmrev.120.000072_bib2","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1111\/bph.14989","article-title":"C3a receptor antagonist therapy is protective with or without thrombolysis in murine thromboembolic stroke","volume":"177","author":"Ahmad","year":"2020","journal-title":"Br J Pharmacol"},{"key":"10.1124\/pharmrev.120.000072_bib3","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1053\/j.ackd.2019.12.003","article-title":"C3 glomerulopathy: pathogenesis and treatment","volume":"27","author":"Ahmad","year":"2020","journal-title":"Adv Chronic Kidney Dis"},{"key":"10.1124\/pharmrev.120.000072_bib4","doi-asserted-by":"crossref","first-page":"417","DOI":"10.3389\/fimmu.2015.00417","article-title":"Complement in the homeostatic and ischemic brain","volume":"6","author":"Alawieh","year":"2015","journal-title":"Front Immunol"},{"key":"10.1124\/pharmrev.120.000072_bib5","doi-asserted-by":"crossref","first-page":"6459","DOI":"10.1126\/scitranslmed.aao6459","article-title":"Targeted complement inhibition salvages stressed neurons and inhibits neuroinflammation after stroke in mice","volume":"10","author":"Alawieh","year":"2018","journal-title":"Sci Transl Med"},{"key":"10.1124\/pharmrev.120.000072_bib6","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1523\/JNEUROSCI.2197-17.2018","article-title":"Identifying the role of complement in triggering neuroinflammation after traumatic brain injury","volume":"38","author":"Alawieh","year":"2018","journal-title":"J Neurosci"},{"key":"10.1124\/pharmrev.120.000072_bib7","doi-asserted-by":"crossref","first-page":"4042","DOI":"10.1523\/JNEUROSCI.2462-19.2020","article-title":"Complement-dependent synaptic uptake and cognitive decline after stroke and reperfusion therapy","volume":"40","author":"Alawieh","year":"2020","journal-title":"J Neurosci"},{"key":"10.1124\/pharmrev.120.000072_bib8","doi-asserted-by":"crossref","first-page":"917","DOI":"10.3389\/fimmu.2020.00917","article-title":"Complement inhibitor therapy for myasthenia gravis","volume":"11","author":"Albazli","year":"2020","journal-title":"Front Immunol"},{"key":"10.1124\/pharmrev.120.000072_bib9","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.4049\/jimmunol.170.3.1374","article-title":"Natural substrates and inhibitors of mannan-binding lectin-associated serine protease-1 and -2: a study on recombinant catalytic fragments","volume":"170","author":"Ambrus","year":"2003","journal-title":"J Immunol"},{"key":"10.1124\/pharmrev.120.000072_bib10","doi-asserted-by":"crossref","first-page":"6341","DOI":"10.4049\/jimmunol.166.10.6341","article-title":"Identification of a selective nonpeptide antagonist of the anaphylatoxin C3a receptor that demonstrates antiinflammatory activity in animal models","volume":"166","author":"Ames","year":"2001","journal-title":"J Immunol"},{"key":"10.1124\/pharmrev.120.000072_bib11","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1182\/blood-2003-12-4359","article-title":"Deficiency of somatic hypermutation of the antibody light chain is associated with increased frequency of severe respiratory tract infection in common variable immunodeficiency","volume":"105","author":"Andersen","year":"2005","journal-title":"Blood"},{"key":"10.1124\/pharmrev.120.000072_bib12","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1159\/000508920","article-title":"Atypical hemolytic uremic syndrome: new challenges in the complement blockage era","volume":"144","author":"Avila Bernabeu","year":"2020","journal-title":"Nephron"},{"key":"10.1124\/pharmrev.120.000072_bib13","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1080\/1744666X.2020.1792779","article-title":"A new case of congenital ficolin-3 deficiency with primary immunodeficiency","volume":"16","author":"Babaha","year":"2020","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1124\/pharmrev.120.000072_bib14","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.15252\/embj.201591881","article-title":"Complement activation, regulation, and molecular basis for complement-related diseases","volume":"34","author":"Bajic","year":"2015","journal-title":"EMBO J"},{"key":"10.1124\/pharmrev.120.000072_bib15","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1080\/00365540701522959","article-title":"The pharmacokinetic profile of plasma-derived mannan-binding lectin in healthy adult volunteers and patients with Staphylococcus aureus septicaemia","volume":"40","author":"Bang","year":"2008","journal-title":"Scand J Infect Dis"},{"key":"10.1124\/pharmrev.120.000072_bib16","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.clim.2013.02.014","article-title":"Targeting the complement system in systemic lupus erythematosus and other diseases","volume":"148","author":"Barilla-Labarca","year":"2013","journal-title":"Clin Immunol"},{"key":"10.1124\/pharmrev.120.000072_bib17","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1093\/rheumatology\/kew040","article-title":"Complement activation is a crucial pathogenic factor in catastrophic antiphospholipid syndrome","volume":"55","author":"Barratt-Due","year":"2016","journal-title":"Rheumatology (Oxford)"},{"key":"10.1124\/pharmrev.120.000072_bib18","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.imbio.2012.07.019","article-title":"Bride and groom in systemic inflammation--the bells ring for complement and Toll in cooperation","volume":"217","author":"Barratt-Due","year":"2012","journal-title":"Immunobiology"},{"key":"10.1124\/pharmrev.120.000072_bib19","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1189\/jlb.3VMR0316-132R","article-title":"Dual inhibition of complement and Toll-like receptors as a novel approach to treat inflammatory diseases-C3 or C5 emerge together with CD14 as promising targets","volume":"101","author":"Barratt-Due","year":"2017","journal-title":"J Leukoc Biol"},{"key":"10.1124\/pharmrev.120.000072_bib20","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1097\/MCD.0000000000000256","article-title":"Novel mutation in MASP1 gene in a new family with 3MC syndrome","volume":"28","author":"Basdemirci","year":"2019","journal-title":"Clin Dysmorphol"},{"key":"10.1124\/pharmrev.120.000072_bib21","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1038\/ki.2012.373","article-title":"Low mannose-binding lectin serum levels are associated with reduced kidney graft survival","volume":"83","author":"Bay","year":"2013","journal-title":"Kidney Int"},{"key":"10.1124\/pharmrev.120.000072_bib22","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0114883","article-title":"Genetic variation of COLEC10 and COLEC11 and association with serum levels of collectin liver 1 (CL-L1) and collectin kidney 1 (CL-K1)","volume":"10","author":"Bayarri-Olmos","year":"2015","journal-title":"PLoS One"},{"key":"10.1124\/pharmrev.120.000072_bib23","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.3389\/fimmu.2018.02238","article-title":"Development of a quantitative assay for the characterization of human collectin-11 (CL-11, CL-K1)","volume":"9","author":"Bayarri-Olmos","year":"2018","journal-title":"Front Immunol"},{"key":"10.1124\/pharmrev.120.000072_bib24","doi-asserted-by":"crossref","first-page":"3942","DOI":"10.1038\/s41467-020-17405-z","article-title":"Multiscale causal networks identify VGF as a key regulator of Alzheimer\u2019s disease","volume":"11","author":"Beckmann","year":"2020","journal-title":"Nat Commun"},{"key":"10.1124\/pharmrev.120.000072_bib25","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s40265-019-1065-0","article-title":"Therapies directed against B-cells and downstream effectors in generalized autoimmune myasthenia gravis: current status","volume":"79","author":"Beecher","year":"2019","journal-title":"Drugs"},{"key":"10.1124\/pharmrev.120.000072_bib26","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0164646","article-title":"Characterization of pharmacologic and pharmacokinetic properties of CCX168, a potent and selective orally administered complement 5a receptor inhibitor, based on preclinical evaluation and randomized phase 1 clinical study","volume":"11","author":"Bekker","year":"2016","journal-title":"PLoS One"},{"key":"10.1124\/pharmrev.120.000072_bib27","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1089\/08977150152725605","article-title":"Complement activation in the human brain after traumatic head injury","volume":"18","author":"Bellander","year":"2001","journal-title":"J Neurotrauma"},{"key":"10.1124\/pharmrev.120.000072_bib28","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/j.ejpn.2015.07.001","article-title":"Devastating recurrent brain ischemic infarctions and retinal disease in pediatric patients with CD59 deficiency","volume":"19","author":"Ben-Zeev","year":"2015","journal-title":"Eur J Paediatr Neurol"},{"key":"10.1124\/pharmrev.120.000072_bib29","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1042\/bj2160385","article-title":"Biosynthesis in vitro of complement subcomponents C1q, C1s and C1 inhibitor by resting and stimulated human monocytes","volume":"216","author":"Bensa","year":"1983","journal-title":"Biochem J"},{"key":"10.1124\/pharmrev.120.000072_bib30","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.nbd.2015.02.004","article-title":"A novel anticonvulsant mechanism via inhibition of complement receptor C5ar1 in murine epilepsy models","volume":"76","author":"Benson","year":"2015","journal-title":"Neurobiol Dis"},{"key":"10.1124\/pharmrev.120.000072_bib31","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1053\/j.seminhematol.2018.04.002","article-title":"Complement activation and inhibition in autoimmune hemolytic anemia: focus on cold agglutinin disease","volume":"55","author":"Berentsen","year":"2018","journal-title":"Semin Hematol"},{"key":"10.1124\/pharmrev.120.000072_bib32","doi-asserted-by":"crossref","first-page":"3532","DOI":"10.4049\/jimmunol.1103693","article-title":"Exhaustion of cytotoxic effector systems may limit monoclonal antibody-based immunotherapy in cancer patients","volume":"188","author":"Beurskens","year":"2012","journal-title":"J Immunol"},{"key":"10.1124\/pharmrev.120.000072_bib33","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/0167-5699(91)90007-G","article-title":"Complement lysis: a hole is a hole","volume":"12","author":"Bhakdi","year":"1991","journal-title":"Immunol Today"},{"key":"10.1124\/pharmrev.120.000072_bib34","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1008168","article-title":"Herpes simplex encephalitis in adult patients with MASP-2 deficiency","volume":"15","author":"Bibert","year":"2019","journal-title":"PLoS Pathog"},{"key":"10.1124\/pharmrev.120.000072_bib35","doi-asserted-by":"crossref","first-page":"209","DOI":"10.4049\/jimmunol.145.1.209","article-title":"The complement SC5b-9 complex mediates cell adhesion through a vitronectin receptor","volume":"145","author":"Biesecker","year":"1990","journal-title":"J Immunol"},{"key":"10.1124\/pharmrev.120.000072_bib36","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S0162-3109(99)00020-X","article-title":"Derivation of RNA aptamer inhibitors of human complement C5","volume":"42","author":"Biesecker","year":"1999","journal-title":"Immunopharmacology"},{"key":"10.1124\/pharmrev.120.000072_bib37","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1172\/JCI200112023","article-title":"A family with complement factor D deficiency","volume":"108","author":"Biesma","year":"2001","journal-title":"J Clin Invest"},{"key":"10.1124\/pharmrev.120.000072_bib38","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/j.1365-2567.2007.02535.x","article-title":"Studies on the interactions between C-reactive protein and complement proteins","volume":"121","author":"B\u00edr\u00f3","year":"2007","journal-title":"Immunology"},{"key":"10.1124\/pharmrev.120.000072_bib39","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1016\/j.molimm.2003.12.002","article-title":"Complement inhibitor C4b-binding protein-friend or foe in the innate immune system?","volume":"40","author":"Blom","year":"2004","journal-title":"Mol Immunol"},{"key":"10.1124\/pharmrev.120.000072_bib40","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.3389\/fimmu.2019.01308","article-title":"Complement nomenclature-deconvoluted","volume":"10","author":"Bohlson","year":"2019","journal-title":"Front Immunol"},{"key":"10.1124\/pharmrev.120.000072_bib41","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.neulet.2005.07.015","article-title":"C3a expressed in the central nervous system protects against LPS-induced shock","volume":"387","author":"Boos","year":"2005","journal-title":"Neurosci Lett"},{"key":"10.1124\/pharmrev.120.000072_bib42","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s12016-019-08741-0","article-title":"Complement system: a neglected pathway in immunotherapy","volume":"58","author":"Bordron","year":"2020","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1124\/pharmrev.120.000072_bib43","doi-asserted-by":"crossref","first-page":"4209","DOI":"10.1073\/pnas.1311968111","article-title":"C1q as a unique player in angiogenesis with therapeutic implication in wound healing","volume":"111","author":"Bossi","year":"2014","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/pharmrev.120.000072_bib44","doi-asserted-by":"crossref","first-page":"2774","DOI":"10.1016\/j.molimm.2009.04.029","article-title":"Complement in human diseases: lessons from complement deficiencies","volume":"46","author":"Botto","year":"2009","journal-title":"Mol Immunol"},{"key":"10.1124\/pharmrev.120.000072_bib45","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.molimm.2019.07.014","article-title":"Key role of the number of complement receptor 1 on erythrocytes for binding of Escherichia coli to erythrocytes and for leukocyte phagocytosis and oxidative burst in human whole blood","volume":"114","author":"Brekke","year":"2019","journal-title":"Mol Immunol"},{"key":"10.1124\/pharmrev.120.000072_bib46","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1182\/blood-2007-06-094136","article-title":"Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria","volume":"111","author":"Brodsky","year":"2008","journal-title":"Blood"},{"key":"10.1124\/pharmrev.120.000072_bib47","doi-asserted-by":"crossref","first-page":"3496","DOI":"10.4049\/jimmunol.0900445","article-title":"Mannose-binding lectin (MBL) substitution: recovery of opsonic function in vivo lags behind MBL serum levels","volume":"183","author":"Brouwer","year":"2009","journal-title":"J Immunol"},{"key":"10.1124\/pharmrev.120.000072_bib48","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1681\/ASN.2013050453","article-title":"Comprehensive genetic analysis of complement and coagulation genes in atypical hemolytic uremic syndrome","volume":"25","author":"Bu","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"10.1124\/pharmrev.120.000072_bib49","first-page":"699","article-title":"Zur Nomenklatur der schutzenden Eiweisskorper","volume":"10","author":"Buchner","year":"1891","journal-title":"Centr Bakteriol Parasitenk"},{"key":"10.1124\/pharmrev.120.000072_bib50","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.coph.2012.08.001","article-title":"Monoclonal antibody therapeutics: history and future","volume":"12","author":"Buss","year":"2012","journal-title":"Curr Opin Pharmacol"},{"key":"10.1124\/pharmrev.120.000072_bib51","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.immuni.2012.08.002","article-title":"Regulation of humoral immunity by complement","volume":"37","author":"Carroll","year":"2012","journal-title":"Immunity"},{"key":"10.1124\/pharmrev.120.000072_bib52","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.addr.2011.06.005","article-title":"Complement in health and disease","volume":"63","author":"Carroll","year":"2011","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1124\/pharmrev.120.000072_bib53","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/s41586-020-2600-6","article-title":"Association of COVID-19 inflammation with activation of the C5a-C5aR1 axis","volume":"588","author":"Carvelli","year":"2020","journal-title":"Nature"},{"key":"10.1124\/pharmrev.120.000072_bib54","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.3389\/fimmu.2019.01869","article-title":"Editorial: the role of complement in health and disease","volume":"10","author":"Cedzy\u0144ski","year":"2019","journal-title":"Front Immunol"},{"key":"10.1124\/pharmrev.120.000072_bib55","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/S2213-2600(13)70001-8","article-title":"Mannose-binding lectin deficiency and disease severity in non-cystic fibrosis bronchiectasis: a prospective study","volume":"1","author":"Chalmers","year":"2013","journal-title":"Lancet Respir Med"},{"key":"10.1124\/pharmrev.120.000072_bib56","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1111\/jth.14981","article-title":"COVID-19: a collision of complement, coagulation and inflammatory pathways","volume":"18","author":"Chauhan","year":"2020","journal-title":"J Thromb Haemost"},{"key":"10.1124\/pharmrev.120.000072_bib57","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1038\/nri2873","article-title":"Sterile inflammation: sensing and reacting to damage","volume":"10","author":"Chen","year":"2010","journal-title":"Nat Rev Immunol"},{"key":"10.1124\/pharmrev.120.000072_bib58","doi-asserted-by":"crossref","first-page":"2870","DOI":"10.1002\/eji.201040323","article-title":"Inhibition of the alternative pathway of complement activation reduces inflammation in experimental autoimmune uveoretinitis","volume":"40","author":"Chen","year":"2010","journal-title":"Eur J Immunol"},{"key":"10.1124\/pharmrev.120.000072_bib59","doi-asserted-by":"crossref","first-page":"23818","DOI":"10.1074\/jbc.M701078200","article-title":"Accelerating amyloid-beta fibrillization reduces oligomer levels and functional deficits in Alzheimer disease mouse models","volume":"282","author":"Cheng","year":"2007","journal-title":"J Biol Chem"},{"key":"10.1124\/pharmrev.120.000072_bib60","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1002\/eji.1830260312","article-title":"A functional analysis of recombinant soluble CD46 in vivo and a comparison with recombinant soluble forms of CD55 and CD35 in vitro","volume":"26","author":"Christiansen","year":"1996","journal-title":"Eur J Immunol"},{"key":"10.1124\/pharmrev.120.000072_bib61","doi-asserted-by":"crossref","first-page":"7975","DOI":"10.1073\/pnas.0913449107","article-title":"Enhanced synaptic connectivity and epilepsy in C1q knockout mice","volume":"107","author":"Chu","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/pharmrev.120.000072_bib62","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1038\/s41593-020-0672-0","article-title":"The endogenous neuronal complement inhibitor SRPX2 protects against complement-mediated synapse elimination during development","volume":"23","author":"Cong","year":"2020","journal-title":"Nat Neurosci"},{"key":"10.1124\/pharmrev.120.000072_bib63","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1111\/jth.15050","article-title":"Is the COVID-19 thrombotic catastrophe complement-connected?","volume":"18","author":"Conway","year":"2020","journal-title":"J Thromb Haemost"},{"key":"10.1124\/pharmrev.120.000072_bib64","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/j.1365-2249.2009.04070.x","article-title":"Systemic and local anti-C5 therapy reduces the disease severity in experimental autoimmune uveoretinitis","volume":"159","author":"Copland","year":"2010","journal-title":"Clin Exp Immunol"},{"key":"10.1124\/pharmrev.120.000072_bib65","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1172\/JCI110764","article-title":"Primate erythrocyte-immune complex-clearing mechanism","volume":"71","author":"Cornacoff","year":"1983","journal-title":"J Clin Invest"},{"key":"10.1124\/pharmrev.120.000072_bib66","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.abb.2006.02.006","article-title":"Mannan-binding lectin-associated serine protease 3 cleaves synthetic peptides and insulin-like growth factor-binding protein 5","volume":"449","author":"Cortesio","year":"2006","journal-title":"Arch Biochem Biophys"},{"key":"10.1124\/pharmrev.120.000072_bib67","doi-asserted-by":"crossref","first-page":"3542","DOI":"10.4049\/jimmunol.1403068","article-title":"Is the complement activation product C3a a proinflammatory molecule? Re-evaluating the evidence and the myth","volume":"194","author":"Coulthard","year":"2015","journal-title":"J Immunol"},{"key":"10.1124\/pharmrev.120.000072_bib68","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.jaci.2020.05.006","article-title":"Complement activation in patients with COVID-19: A novel therapeutic target","volume":"146","author":"Cugno","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"10.1124\/pharmrev.120.000072_bib69","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.trim.2019.01.004","article-title":"Mannose binding lectin 2 gene polymorphisms in patients after renal transplantation with acute graft rejection","volume":"54","author":"Czerewaty","year":"2019","journal-title":"Transpl Immunol"},{"key":"10.1124\/pharmrev.120.000072_bib70","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/j.jaip.2019.07.039","article-title":"Fatal pneumococcus meningitis in a child with complement factor ficolin-3 deficiency","volume":"8","author":"Dadfar","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1124\/pharmrev.120.000072_bib71","doi-asserted-by":"crossref","first-page":"630","DOI":"10.4049\/jimmunol.117.2.630","article-title":"C3 requirements for formation of alternative pathway C5 convertase","volume":"117","author":"Daha","year":"1976","journal-title":"J Immunol"},{"key":"10.1124\/pharmrev.120.000072_bib72","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1126\/science.1111655","article-title":"Genetics. Was the human genome project worth the effort?","volume":"308","author":"Daiger","year":"2005","journal-title":"Science"},{"key":"10.1124\/pharmrev.120.000072_bib73","doi-asserted-by":"crossref","first-page":"6562","DOI":"10.4081\/hr.2016.6562","article-title":"Positive impact of eculizumab therapy on surgery for budd-chiari syndrome in a patient with paroxysmal nocturnal hemoglobinuria and a long-term history of thrombosis","volume":"8","author":"De-la-Iglesia","year":"2016","journal-title":"Hematol Rep"},{"key":"10.1124\/pharmrev.120.000072_bib74","doi-asserted-by":"crossref","first-page":"7371","DOI":"10.4049\/jimmunol.0902388","article-title":"MAp44, a human protein associated with pattern recognition molecules of the complement system and regulating the lectin pathway of complement activation","volume":"183","author":"Degn","year":"2009","journal-title":"J Immunol"},{"key":"10.1124\/pharmrev.120.000072_bib75","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.ajhg.2011.05.011","article-title":"Disease-causing mutations in genes of the complement system","volume":"88","author":"Degn","year":"2011","journal-title":"Am J Hum Genet"},{"key":"10.1124\/pharmrev.120.000072_bib76","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1016\/j.neuron.2018.10.014","article-title":"Changes in the synaptic proteome in tauopathy and rescue of tau-induced synapse loss by C1q antibodies","volume":"100","author":"Dejanovic","year":"2018","journal-title":"Neuron"},{"key":"10.1124\/pharmrev.120.000072_bib77","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1159\/000338194","article-title":"Damage- and pathogen-associated molecular patterns and alarmins: keys to sepsis?","volume":"48","author":"Denk","year":"2012","journal-title":"Eur Surg Res"},{"key":"10.1124\/pharmrev.120.000072_bib78","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s40265-018-0875-9","article-title":"Eculizumab: a review in generalized myasthenia gravis","volume":"78","author":"Dhillon","year":"2018","journal-title":"Drugs"},{"key":"10.1124\/pharmrev.120.000072_bib79","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.kint.2017.09.018","article-title":"C5a receptor 1 promotes autoimmunity, neutrophil dysfunction and injury in experimental anti-myeloperoxidase glomerulonephritis","volume":"93","author":"Dick","year":"2018","journal-title":"Kidney Int"},{"key":"10.1124\/pharmrev.120.000072_bib80","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1126\/science.1248943","article-title":"Complement is activated by IgG hexamers assembled at the cell surface","volume":"343","author":"Diebolder","year":"2014","journal-title":"Science"},{"key":"10.1124\/pharmrev.120.000072_bib81","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1111\/imr.12460","article-title":"The emerging roles of mannose-binding lectin-associated serine proteases (MASPs) in the lectin pathway of complement and beyond","volume":"274","author":"Dob\u00f3","year":"2016","journal-title":"Immunol Rev"},{"key":"10.1124\/pharmrev.120.000072_bib82","doi-asserted-by":"crossref","first-page":"31877","DOI":"10.1038\/srep31877","article-title":"MASP-3 is the exclusive pro-factor D activator in resting blood: the lectin and the alternative complement pathways are fundamentally linked","volume":"6","author":"Dob\u00f3","year":"2016","journal-title":"Sci Rep"},{"key":"10.1124\/pharmrev.120.000072_bib83","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1016\/j.imbio.2012.07.004","article-title":"Interactions of the humoral pattern recognition molecule PTX3 with the complement system","volume":"217","author":"Doni","year":"2012","journal-title":"Immunobiology"},{"key":"10.1124\/pharmrev.120.000072_bib84","first-page":"1040","article-title":"Complex two-gene modulation of lung disease severity in children with cystic fibrosis","volume":"118","author":"Dorfman","year":"2008","journal-title":"J Clin Invest"},{"key":"10.1124\/pharmrev.120.000072_bib85","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1097\/MOT.0b013e32834253c7","article-title":"Pentraxins (CRP, SAP) in the process of complement activation and clearance of apoptotic bodies through Fc\u03b3 receptors","volume":"16","author":"Du Clos","year":"2011","journal-title":"Curr Opin Organ Transplant"},{"key":"10.1124\/pharmrev.120.000072_bib86","first-page":"6","article-title":"Zur theorie der lysinwirkung","volume":"1","author":"Ehrlich","year":"1899","journal-title":"Berliner Klinische Wochenschrift"},{"key":"10.1124\/pharmrev.120.000072_bib87","doi-asserted-by":"crossref","first-page":"317","DOI":"10.2119\/molmed.2010.00149","article-title":"New insights of an old defense system: structure, function, and clinical relevance of the complement system","volume":"17","author":"Ehrnthaller","year":"2011","journal-title":"Mol Med"},{"key":"10.1124\/pharmrev.120.000072_bib88","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1086\/379324","article-title":"Impact of mannose-binding lectin on susceptibility to infectious diseases","volume":"37","author":"Eisen","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1124\/pharmrev.120.000072_bib89","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/imr.12471","article-title":"Dangerous liaisons: complement, coagulation, and kallikrein\/kinin cross-talk act as a linchpin in the events leading to thromboinflammation","volume":"274","author":"Ekdahl","year":"2016","journal-title":"Immunol Rev"},{"key":"10.1124\/pharmrev.120.000072_bib90","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s13024-020-0357-x","article-title":"VGF-derived peptide TLQP-21 modulates microglial function through C3aR1 signaling pathways and reduces neuropathology in 5xFAD mice","volume":"15","author":"El Gaamouch","year":"2020","journal-title":"Mol Neurodegener"},{"key":"10.1124\/pharmrev.120.000072_bib91","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/bs.ircmb.2015.01.003","article-title":"New insights into the role of ficolins in the lectin pathway of innate immunity","volume":"316","author":"Endo","year":"2015","journal-title":"Int Rev Cell Mol Biol"},{"key":"10.1124\/pharmrev.120.000072_bib92","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.imlet.2015.11.014","article-title":"C4b-binding protein: the good, the bad and the deadly. Novel functions of an old friend","volume":"169","author":"Ermert","year":"2016","journal-title":"Immunol Lett"},{"key":"10.1124\/pharmrev.120.000072_bib93","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/0167-5699(91)90006-F","article-title":"Big MAC attack: complement proteins cause leaky patches","volume":"12","author":"Esser","year":"1991","journal-title":"Immunol Today"},{"key":"10.1124\/pharmrev.120.000072_bib94","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1053\/j.ajkd.2015.12.034","article-title":"Terminal complement inhibitor eculizumab in adult patients with atypical hemolytic uremic syndrome: a single-arm, open-label trial","volume":"68","author":"Fakhouri","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"10.1124\/pharmrev.120.000072_bib95","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1084\/jem.152.1.20","article-title":"Identification of the membrane glycoprotein that is the C3b receptor of the human erythrocyte, polymorphonuclear leukocyte, B lymphocyte, and monocyte","volume":"152","author":"Fearon","year":"1980","journal-title":"J Exp Med"},{"key":"10.1124\/pharmrev.120.000072_bib96","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1111\/j.1365-2249.2005.02951.x","article-title":"Common variable immunodeficiency and the complement system; low mannose-binding lectin levels are associated with bronchiectasis","volume":"142","author":"Fevang","year":"2005","journal-title":"Clin Exp Immunol"},{"key":"10.1124\/pharmrev.120.000072_bib97","doi-asserted-by":"crossref","first-page":"752","DOI":"10.3389\/fimmu.2019.00752","article-title":"Complement C5b-9 and cancer: mechanisms of cell damage, cancer counteractions, and approaches for intervention","volume":"10","author":"Fishelson","year":"2019","journal-title":"Front Immunol"},{"key":"10.1124\/pharmrev.120.000072_bib98","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.autrev.2005.09.006","article-title":"Complement, natural antibodies, autoantibodies and tissue injury","volume":"5","author":"Fleming","year":"2006","journal-title":"Autoimmun Rev"},{"key":"10.1124\/pharmrev.120.000072_bib99","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.thromres.2020.06.027","article-title":"Is COVID-19 associated thrombosis caused by overactivation of the complement cascade? A literature review","volume":"194","author":"Fletcher-Sandersj\u00f6\u00f6","year":"2020","journal-title":"Thromb Res"},{"key":"10.1124\/pharmrev.120.000072_bib100","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.kint.2018.03.009","article-title":"IgA nephropathy: new insights into the role of complement","volume":"94","author":"Floege","year":"2018","journal-title":"Kidney Int"},{"key":"10.1124\/pharmrev.120.000072_bib101","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.4049\/jimmunol.0901005","article-title":"Treatment with a C5aR antagonist decreases pathology and enhances behavioral performance in murine models of Alzheimer\u2019s disease","volume":"183","author":"Fonseca","year":"2009","journal-title":"J Immunol"},{"key":"10.1124\/pharmrev.120.000072_bib102","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1742-2094-8-4","article-title":"Contribution of complement activation pathways to neuropathology differs among mouse models of Alzheimer\u2019s disease","volume":"8","author":"Fonseca","year":"2011","journal-title":"J Neuroinflammation"},{"key":"10.1124\/pharmrev.120.000072_bib103","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.15252\/embj.201593673","article-title":"Regulators of complement activity mediate inhibitory mechanisms through a common C3b-binding mode","volume":"35","author":"Forneris","year":"2016","journal-title":"EMBO J"},{"key":"10.1124\/pharmrev.120.000072_bib104","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1007\/s40265-020-01297-w","article-title":"Eculizumab: a review in neuromyelitis optica spectrum disorder","volume":"80","author":"Frampton","year":"2020","journal-title":"Drugs"},{"key":"10.1124\/pharmrev.120.000072_bib105","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.jim.2018.08.001","article-title":"The effect on the immunology laboratory of the expansion in complement therapeutics","volume":"461","author":"Frazer-Abel","year":"2018","journal-title":"J Immunol Methods"},{"key":"10.1124\/pharmrev.120.000072_bib106","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1038\/ni.1625","article-title":"Structure of and influence of a tick complement inhibitor on human complement component 5","volume":"9","author":"Fredslund","year":"2008","journal-title":"Nat Immunol"},{"key":"10.1124\/pharmrev.120.000072_bib107","doi-asserted-by":"crossref","first-page":"4705","DOI":"10.1182\/blood-2011-06-359646","article-title":"Design and development of TT30, a novel C3d-targeted C3\/C5 convertase inhibitor for treatment of human complement alternative pathway-mediated diseases","volume":"118","author":"Fridkis-Hareli","year":"2011","journal-title":"Blood"},{"key":"10.1124\/pharmrev.120.000072_bib108","doi-asserted-by":"crossref","first-page":"530","DOI":"10.3389\/fimmu.2020.00530","article-title":"Assessment of the role of C3(H2O) in the alternative pathway","volume":"11","author":"Fromell","year":"2020","journal-title":"Front Immunol"},{"key":"10.1124\/pharmrev.120.000072_bib109","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1093\/intimm\/1.1.85","article-title":"A high incidence of C9 deficiency among healthy blood donors in Osaka, Japan","volume":"1","author":"Fukumori","year":"1989","journal-title":"Int Immunol"},{"key":"10.1124\/pharmrev.120.000072_bib110","doi-asserted-by":"crossref","first-page":"288","DOI":"10.3389\/fimmu.2017.00288","article-title":"Lectin pathway of complement activation is associated with vulnerability of atherosclerotic plaques","volume":"8","author":"Fumagalli","year":"2017","journal-title":"Front Immunol"},{"key":"10.1124\/pharmrev.120.000072_bib111","doi-asserted-by":"crossref","first-page":"46974","DOI":"10.1074\/jbc.M307764200","article-title":"The crystal structure of the globular head of complement protein C1q provides a basis for its versatile recognition properties","volume":"278","author":"Gaboriaud","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1124\/pharmrev.120.000072_bib112","first-page":"298","article-title":"Failure of first meningococcal vaccination in patients with atypical haemolytic uraemic syndrome treated with eculizumab","volume":"35","author":"G\u00e4ckler","year":"2020","journal-title":"Nephrol Dial Transplant"},{"key":"10.1124\/pharmrev.120.000072_bib113","doi-asserted-by":"crossref","first-page":"5483","DOI":"10.3390\/ijms21155483","article-title":"Association of polymorphisms of MASP1\/3, COLEC10, and COLEC11 genes with 3MC syndrome","volume":"21","author":"Gajek","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1124\/pharmrev.120.000072_bib114","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s10875-019-00714-4","article-title":"Should MASP-2 deficiency be considered a primary immunodeficiency? Relevance of the lectin pathway","volume":"40","author":"Garc\u00eda-Laorden","year":"2020","journal-title":"J Clin Immunol"},{"key":"10.1124\/pharmrev.120.000072_bib115","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1111\/imr.12468","article-title":"A journey through the lectin pathway of complement-MBL and beyond","volume":"274","author":"Garred","year":"2016","journal-title":"Immunol Rev"},{"key":"10.1124\/pharmrev.120.000072_bib116","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0161-5890(03)00104-4","article-title":"Mannose-binding lectin deficiency--revisited","volume":"40","author":"Garred","year":"2003","journal-title":"Mol Immunol"},{"key":"10.1124\/pharmrev.120.000072_bib117","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/sj.gene.6364283","article-title":"Mannose-binding lectin and its genetic variants","volume":"7","author":"Garred","year":"2006","journal-title":"Genes Immun"},{"key":"10.1124\/pharmrev.120.000072_bib118","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1002\/ppul.10064","article-title":"Mannose-binding lectin (MBL) therapy in an MBL-deficient patient with severe cystic fibrosis lung disease","volume":"33","author":"Garred","year":"2002","journal-title":"Pediatr Pulmonol"},{"key":"10.1124\/pharmrev.120.000072_bib119","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1172\/JCI6861","article-title":"Association of mannose-binding lectin gene heterogeneity with severity of lung disease and survival in cystic fibrosis","volume":"104","author":"Garred","year":"1999","journal-title":"J Clin Invest"},{"key":"10.1124\/pharmrev.120.000072_bib120","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.brainres.2009.04.047","article-title":"Synergistic neuroprotective effects of C3a and C5a receptor blockade following intracerebral hemorrhage","volume":"1298","author":"Garrett","year":"2009","journal-title":"Brain Res"},{"key":"10.1124\/pharmrev.120.000072_bib121","doi-asserted-by":"crossref","first-page":"e227","DOI":"10.1111\/bjh.16783","article-title":"Severe COVID-19 infection and thrombotic microangiopathy: success does not come easily","volume":"189","author":"Gavriilaki","year":"2020","journal-title":"Br J Haematol"},{"key":"10.1124\/pharmrev.120.000072_bib122","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.2337\/dc20-0345","article-title":"Mannose-binding lectin and risk of cardiovascular events and mortality in type 2 diabetes: a Danish cohort study","volume":"43","author":"Gedebjerg","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1124\/pharmrev.120.000072_bib123","doi-asserted-by":"crossref","first-page":"101338","DOI":"10.1016\/j.smim.2019.101338","article-title":"The C1q Receptors: focus on gC1qR\/p33 (C1qBP, p32, HABP-1)1","volume":"45","author":"Ghebrehiwet","year":"2019","journal-title":"Semin Immunol"},{"key":"10.1124\/pharmrev.120.000072_bib124","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/978-1-62703-724-2_26","article-title":"Purification of C1q receptors and functional analysis","volume":"1100","author":"Ghebrehiwet","year":"2014","journal-title":"Methods Mol Biol"},{"key":"10.1124\/pharmrev.120.000072_bib125","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.molimm.2018.05.023","article-title":"Novel potential inhibitors of complement system and their roles in complement regulation and beyond","volume":"102","author":"Gialeli","year":"2018","journal-title":"Mol Immunol"},{"key":"10.1124\/pharmrev.120.000072_bib126","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/bjd.18877","article-title":"Clinical efficacy of complement C5a inhibition by IFX-1 in hidradenitis suppurativa: an open-label single-arm trial in patients not eligible for adalimumab","volume":"183","author":"Giamarellos-Bourboulis","year":"2020","journal-title":"Br J Dermatol"},{"key":"10.1124\/pharmrev.120.000072_bib127","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.molimm.2018.06.011","article-title":"Common and rare genetic variants of complement components in human disease","volume":"102","author":"Goicoechea de Jorge","year":"2018","journal-title":"Mol Immunol"},{"key":"10.1124\/pharmrev.120.000072_bib128","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/j.kint.2015.11.025","article-title":"Polymorphisms in the lectin pathway of complement activation influence the incidence of acute rejection and graft outcome after kidney transplantation","volume":"89","author":"Golshayan","year":"2016","journal-title":"Kidney Int"},{"key":"10.1124\/pharmrev.120.000072_bib129","doi-asserted-by":"crossref","first-page":"919","DOI":"10.3390\/jcm8070919","article-title":"Outcomes of kidney transplant patients with atypical hemolytic uremic syndrome treated with eculizumab: a systematic review and meta-analysis","volume":"8","author":"Gonzalez Suarez","year":"2019","journal-title":"J Clin Med"},{"key":"10.1124\/pharmrev.120.000072_bib130","doi-asserted-by":"crossref","first-page":"e01753","DOI":"10.1128\/mBio.01753-18","article-title":"Complement activation contributes to severe acute respiratory syndrome coronavirus pathogenesis","volume":"9","author":"Gralinski","year":"2018","journal-title":"MBio"},{"key":"10.1124\/pharmrev.120.000072_bib131","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.ejmg.2018.01.016","article-title":"Biallelic intragenic deletion in MASP1 in an adult female with 3MC syndrome","volume":"61","author":"Graul-Neumann","year":"2018","journal-title":"Eur J Med Genet"},{"key":"10.1124\/pharmrev.120.000072_bib132","doi-asserted-by":"crossref","first-page":"6303","DOI":"10.1073\/pnas.1722613115","article-title":"Local apoptotic-like mechanisms underlie complement-mediated synaptic pruning","volume":"115","author":"Gy\u00f6rffy","year":"2018","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/pharmrev.120.000072_bib133","doi-asserted-by":"crossref","first-page":"5243","DOI":"10.1007\/s00018-020-03468-0","article-title":"Synaptic mitochondrial dysfunction and septin accumulation are linked to complement-mediated synapse loss in an Alzheimer's disease animal model","volume":"77","author":"Gy\u00f6rffy","year":"2020","journal-title":"Cell Mol Life Sci"},{"key":"10.1124\/pharmrev.120.000072_bib134","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1097\/TP.0000000000002640","article-title":"Eculizumab as primary therapy for active antibody-mediated rejection of renal allografts: a matter of timing, severity, and donor-specific antibodies","volume":"103","author":"Haas","year":"2019","journal-title":"Transplantation"},{"key":"10.1124\/pharmrev.120.000072_bib135","doi-asserted-by":"crossref","first-page":"7227","DOI":"10.1073\/pnas.0501536102","article-title":"A common haplotype in the complement regulatory gene factor H (HF1\/CFH) predisposes individuals to age-related macular degeneration","volume":"102","author":"Hageman","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/pharmrev.120.000072_bib136","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/j.imbio.2012.07.007","article-title":"Complement and dysbiosis in periodontal disease","volume":"217","author":"Hajishengallis","year":"2012","journal-title":"Immunobiology"},{"key":"10.1124\/pharmrev.120.000072_bib137","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1038\/ni.3858","article-title":"Novel mechanisms and functions of complement","volume":"18","author":"Hajishengallis","year":"2017","journal-title":"Nat Immunol"},{"key":"10.1124\/pharmrev.120.000072_bib138","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/j.imbio.2016.05.012","article-title":"The collectins CL-L1, CL-K1 and CL-P1, and their roles in complement and innate immunity","volume":"221","author":"Hansen","year":"2016","journal-title":"Immunobiology"},{"key":"10.1124\/pharmrev.120.000072_bib139","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1111\/j.1365-2249.2006.03072.x","article-title":"Design of a complement mannose-binding lectin pathway-specific activation system applicable at low serum dilutions","volume":"144","author":"Harboe","year":"2006","journal-title":"Clin Exp Immunol"},{"key":"10.1124\/pharmrev.120.000072_bib140","doi-asserted-by":"crossref","first-page":"E534","DOI":"10.1073\/pnas.1612385114","article-title":"Properdin binding to complement activating surfaces depends on initial C3b deposition","volume":"114","author":"Harboe","year":"2017","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/pharmrev.120.000072_bib141","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1111\/j.1582-4934.2008.00350.x","article-title":"The alternative complement pathway revisited","volume":"12","author":"Harboe","year":"2008","journal-title":"J Cell Mol Med"},{"key":"10.1124\/pharmrev.120.000072_bib142","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/j.addr.2011.05.010","article-title":"Advances in assay of complement function and activation","volume":"63","author":"Harboe","year":"2011","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1124\/pharmrev.120.000072_bib143","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1111\/j.1365-2249.2004.02627.x","article-title":"The quantitative role of alternative pathway amplification in classical pathway induced terminal complement activation","volume":"138","author":"Harboe","year":"2004","journal-title":"Clin Exp Immunol"},{"key":"10.1124\/pharmrev.120.000072_bib144","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.it.2012.06.001","article-title":"The complotype: dictating risk for inflammation and infection","volume":"33","author":"Harris","year":"2012","journal-title":"Trends Immunol"},{"key":"10.1124\/pharmrev.120.000072_bib145","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.molimm.2018.06.008","article-title":"Developments in anti-complement therapy; from disease to clinical trial","volume":"102","author":"Harris","year":"2018","journal-title":"Mol Immunol"},{"key":"10.1124\/pharmrev.120.000072_bib146","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1053\/j.semdp.2020.03.001","article-title":"IgA nephropathy: a brief review","volume":"37","author":"Hassler","year":"2020","journal-title":"Semin Diagn Pathol"},{"key":"10.1124\/pharmrev.120.000072_bib147","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.4049\/jimmunol.1900605","article-title":"Cutting edge: role of MASP-3 in the physiological activation of factor D of the alternative complement pathway","volume":"203","author":"Hayashi","year":"2019","journal-title":"J Immunol"},{"key":"10.1124\/pharmrev.120.000072_bib148","doi-asserted-by":"crossref","first-page":"4041","DOI":"10.1016\/j.molimm.2008.07.011","article-title":"A role of macrophage complement receptor CRIg in immune clearance and inflammation","volume":"45","author":"He","year":"2008","journal-title":"Mol Immunol"},{"key":"10.1124\/pharmrev.120.000072_bib149","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1681\/ASN.2006091069","article-title":"Hemolytic uremic syndrome: a factor H mutation (E1172Stop) causes defective complement control at the surface of endothelial cells","volume":"18","author":"Heinen","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"10.1124\/pharmrev.120.000072_bib150","doi-asserted-by":"crossref","first-page":"10498","DOI":"10.1073\/pnas.1202588109","article-title":"Revised mechanism of complement lectin-pathway activation revealing the role of serine protease MASP-1 as the exclusive activator of MASP-2","volume":"109","author":"H\u00e9ja","year":"2012","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/pharmrev.120.000072_bib151","doi-asserted-by":"crossref","first-page":"3071","DOI":"10.1093\/hmg\/ddm265","article-title":"Heterozygosity of mannose-binding lectin (MBL2) genotypes predicts advantage (heterosis) in relation to fatal outcome in intensive care patients","volume":"16","author":"Hellemann","year":"2007","journal-title":"Hum Mol Genet"},{"key":"10.1124\/pharmrev.120.000072_bib152","doi-asserted-by":"crossref","first-page":"6117","DOI":"10.4049\/jimmunol.1302121","article-title":"Heteromeric complexes of native collectin kidney 1 and collectin liver 1 are found in the circulation with MASPs and activate the complement system","volume":"191","author":"Henriksen","year":"2013","journal-title":"J Immunol"},{"key":"10.1124\/pharmrev.120.000072_bib153","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.molimm.2007.06.144","article-title":"Prevention of experimental autoimmune myasthenia gravis by rat Crry-Ig: a model agent for long-term complement inhibition in vivo","volume":"45","author":"Hepburn","year":"2008","journal-title":"Mol Immunol"},{"key":"10.1124\/pharmrev.120.000072_bib154","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s13024-017-0210-z","article-title":"Prevention of C5aR1 signaling delays microglial inflammatory polarization, favors clearance pathways and suppresses cognitive loss","volume":"12","author":"Hernandez","year":"2017","journal-title":"Mol Neurodegener"},{"key":"10.1124\/pharmrev.120.000072_bib155","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1172\/JCI114384","article-title":"Complete and partial deficiencies of complement factor D in a Dutch family","volume":"84","author":"Hiemstra","year":"1989","journal-title":"J Clin Invest"},{"key":"10.1124\/pharmrev.120.000072_bib156","doi-asserted-by":"crossref","first-page":"4985","DOI":"10.1182\/blood-2012-09-311381","article-title":"Thrombosis in paroxysmal nocturnal hemoglobinuria","volume":"121","author":"Hill","year":"2013","journal-title":"Blood"},{"key":"10.1124\/pharmrev.120.000072_bib157","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/bjh.12347","article-title":"Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria","volume":"162","author":"Hillmen","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1124\/pharmrev.120.000072_bib158","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/0167-5699(84)90227-5","article-title":"Agreement now the norm","volume":"5","author":"Hobart","year":"1984","journal-title":"Immunol Today"},{"key":"10.1124\/pharmrev.120.000072_bib159","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1146\/annurev-immunol-032713-120154","article-title":"Complement and its receptors: new insights into human disease","volume":"32","author":"Holers","year":"2014","journal-title":"Annu Rev Immunol"},{"key":"10.1124\/pharmrev.120.000072_bib160","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.3389\/fimmu.2018.01057","article-title":"Complement in the initiation and evolution of rheumatoid arthritis","volume":"9","author":"Holers","year":"2018","journal-title":"Front Immunol"},{"key":"10.1124\/pharmrev.120.000072_bib161","doi-asserted-by":"crossref","first-page":"25018","DOI":"10.1073\/pnas.2010540117","article-title":"Systemic complement activation is associated with respiratory failure in COVID-19 hospitalized patients","volume":"117","author":"Holter","year":"2020","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/pharmrev.120.000072_bib162","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1126\/science.aad8373","article-title":"Complement and microglia mediate early synapse loss in Alzheimer mouse models","volume":"352","author":"Hong","year":"2016","journal-title":"Science"},{"key":"10.1124\/pharmrev.120.000072_bib163","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1001\/jamaneurol.2019.5125","article-title":"Clinical effects of the self-administered subcutaneous complement inhibitor zilucoplan in patients with moderate to severe generalized myasthenia gravis: results of a phase 2 randomized, double-blind, placebo-controlled, multicenter clinical trial","volume":"77","author":"Howard","year":"2020","journal-title":"JAMA Neurol"},{"key":"10.1124\/pharmrev.120.000072_bib164","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/S1474-4422(17)30369-1","article-title":"Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study","volume":"16","author":"Howard","year":"2017","journal-title":"Lancet Neurol"},{"key":"10.1124\/pharmrev.120.000072_bib165","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/1742-2094-10-76","article-title":"Deficiency of complement component 5 ameliorates glaucoma in DBA\/2J mice","volume":"10","author":"Howell","year":"2013","journal-title":"J Neuroinflammation"},{"key":"10.1124\/pharmrev.120.000072_bib166","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1126\/science.285.5427.595","article-title":"Neuronal protection in stroke by an sLex-glycosylated complement inhibitory protein","volume":"285","author":"Huang","year":"1999","journal-title":"Science"},{"key":"10.1124\/pharmrev.120.000072_bib167","doi-asserted-by":"crossref","first-page":"5324","DOI":"10.4049\/jimmunol.1400341","article-title":"Double blockade of CD14 and complement C5 abolishes the cytokine storm and improves morbidity and survival in polymicrobial sepsis in mice","volume":"192","author":"Huber-Lang","year":"2014","journal-title":"J Immunol"},{"key":"10.1124\/pharmrev.120.000072_bib168","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/s41590-018-0064-8","article-title":"Innate immune responses to trauma","volume":"19","author":"Huber-Lang","year":"2018","journal-title":"Nat Immunol"},{"key":"10.1124\/pharmrev.120.000072_bib169","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/j.ajpath.2016.12.019","article-title":"Low-intensity training and the C5a complement antagonist NOX-D21 rescue the mdx phenotype through modulation of inflammation","volume":"187","author":"Hyzewicz","year":"2017","journal-title":"Am J Pathol"},{"key":"10.1124\/pharmrev.120.000072_bib170","doi-asserted-by":"crossref","first-page":"3751","DOI":"10.4049\/jimmunol.1100280","article-title":"The role of mannose-binding lectin-associated serine protease-3 in activation of the alternative complement pathway","volume":"187","author":"Iwaki","year":"2011","journal-title":"J Immunol"},{"key":"10.1124\/pharmrev.120.000072_bib171","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1111\/j.1600-6143.2007.02029.x","article-title":"Successful liver-kidney transplantation in two children with aHUS caused by a mutation in complement factor H","volume":"8","author":"Jalanko","year":"2008","journal-title":"Am J Transplant"},{"key":"10.1124\/pharmrev.120.000072_bib172","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/nature04005","article-title":"Structures of complement component C3 provide insights into the function and evolution of immunity","volume":"437","author":"Janssen","year":"2005","journal-title":"Nature"},{"key":"10.1124\/pharmrev.120.000072_bib173","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.4049\/jimmunol.1900694","article-title":"Circulating ficolin-2 and ficolin-3 form heterocomplexes","volume":"204","author":"Jarlhelt","year":"2020","journal-title":"J Immunol"},{"key":"10.1124\/pharmrev.120.000072_bib174","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.140711","article-title":"The complement system in COVID-19: friend and foe?","volume":"5","author":"Java","year":"2020","journal-title":"JCI Insight"},{"key":"10.1124\/pharmrev.120.000072_bib175","doi-asserted-by":"crossref","first-page":"2756","DOI":"10.1681\/ASN.2016111179","article-title":"Randomized trial of C5a receptor inhibitor avacopan in ANCA-associated vasculitis","volume":"28","author":"Jayne","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"10.1124\/pharmrev.120.000072_bib176","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1042\/bst0310763","article-title":"Recombinant mannan-binding lectin (MBL) for therapy","volume":"31","author":"Jensenius","year":"2003","journal-title":"Biochem Soc Trans"},{"key":"10.1124\/pharmrev.120.000072_bib177","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/s41426-018-0063-8","article-title":"Blockade of the C5a-C5aR axis alleviates lung damage in hDPP4-transgenic mice infected with MERS-CoV","volume":"7","author":"Jiang","year":"2018","journal-title":"Emerg Microbes Infect"},{"key":"10.1124\/pharmrev.120.000072_bib178","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1016\/j.bbmt.2016.03.032","article-title":"Terminal complement blockade after HSCT is safe without meningococcal vaccination","volume":"22","author":"Jodele","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1124\/pharmrev.120.000072_bib179","first-page":"1049","article-title":"Complement blockade for TA-TMA: lessons learned from a large pediatric cohort treated with eculizumab","volume":"135","author":"Jodele","year":"2020","journal-title":"Blood"},{"key":"10.1124\/pharmrev.120.000072_bib180","article-title":"Tackling COVID-19 infection through complement-targeted immunotherapy","author":"Jodele","year":"2020","journal-title":"Br J Pharmacol"},{"key":"10.1124\/pharmrev.120.000072_bib181","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/S0002-9440(10)61205-9","article-title":"Binding of complement factor H to endothelial cells is mediated by the carboxy-terminal glycosaminoglycan binding site","volume":"167","author":"Jokiranta","year":"2005","journal-title":"Am J Pathol"},{"key":"10.1124\/pharmrev.120.000072_bib182","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1083\/jcb.201802148","article-title":"Immune regulation by fibroblasts in tissue injury depends on uPARAP-mediated uptake of collectins","volume":"218","author":"J\u00fcrgensen","year":"2019","journal-title":"J Cell Biol"},{"key":"10.1124\/pharmrev.120.000072_bib183","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/S0161-5890(99)00115-7","article-title":"Complement resistance of tumor cells: basal and induced mechanisms","volume":"36","author":"Jurianz","year":"1999","journal-title":"Mol Immunol"},{"key":"10.1124\/pharmrev.120.000072_bib184","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1016\/S0041-1345(03)00485-8","article-title":"Dose-dependent inhibition of complement in baboons by vaccinia virus complement control protein: implications in xenotransplantation","volume":"35","author":"Kahn","year":"2003","journal-title":"Transplant Proc"},{"key":"10.1124\/pharmrev.120.000072_bib185","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.omtm.2017.08.001","article-title":"Safety and efficacy of the complement inhibitor AMY-101 in a natural model of periodontitis in non-human primates","volume":"6","author":"Kajikawa","year":"2017","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1124\/pharmrev.120.000072_bib186","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1007\/s12185-013-1404-y","article-title":"Long-term efficacy and safety of eculizumab in Japanese patients with PNH: AEGIS trial","volume":"98","author":"Kanakura","year":"2013","journal-title":"Int J Hematol"},{"key":"10.1124\/pharmrev.120.000072_bib187","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1084\/jem.20070432","article-title":"A novel inhibitor of the alternative pathway of complement reverses inflammation and bone destruction in experimental arthritis","volume":"204","author":"Katschke","year":"2007","journal-title":"J Exp Med"},{"key":"10.1124\/pharmrev.120.000072_bib188","doi-asserted-by":"crossref","first-page":"6786","DOI":"10.1182\/blood-2011-02-333997","article-title":"Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival","volume":"117","author":"Kelly","year":"2011","journal-title":"Blood"},{"key":"10.1124\/pharmrev.120.000072_bib189","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.smim.2018.05.002","article-title":"Back to the future - non-canonical functions of complement","volume":"37","author":"Kemper","year":"2018","journal-title":"Semin Immunol"},{"key":"10.1124\/pharmrev.120.000072_bib190","doi-asserted-by":"crossref","first-page":"E6390","DOI":"10.1073\/pnas.1706818114","article-title":"Inhibition of complement C5 protects against organ failure and reduces mortality in a baboon model of Escherichia coli sepsis","volume":"114","author":"Keshari","year":"2017","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/pharmrev.120.000072_bib191","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1053\/j.seminhematol.2018.04.004","article-title":"Congenital defects in the expression of the glycosylphosphatidylinositol-anchored complement regulatory proteins CD59 and decay-accelerating factor","volume":"55","author":"Kinoshita","year":"2018","journal-title":"Semin Hematol"},{"key":"10.1124\/pharmrev.120.000072_bib192","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/j.1365-2249.1993.tb03442.x","article-title":"Complete functional C1q deficiency associated with systemic lupus erythematosus (SLE)","volume":"94","author":"Kirschfink","year":"1993","journal-title":"Clin Exp Immunol"},{"key":"10.1124\/pharmrev.120.000072_bib193","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1182\/blood-2013-01-481499","article-title":"A case of paroxysmal nocturnal hemoglobinuria caused by a germline mutation and a somatic mutation in PIGT","volume":"122","author":"Krawitz","year":"2013","journal-title":"Blood"},{"key":"10.1124\/pharmrev.120.000072_bib194","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1182\/blood-2018-09-876805","article-title":"Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor-experienced adult patients with PNH: the 302 study","volume":"133","author":"Kulasekararaj","year":"2019","journal-title":"Blood"},{"key":"10.1124\/pharmrev.120.000072_bib195","doi-asserted-by":"crossref","first-page":"e141","DOI":"10.1111\/bjh.16916","article-title":"Terminal complement inhibition dampens the inflammation during COVID-19","volume":"190","author":"Kulasekararaj","year":"2020","journal-title":"Br J Haematol"},{"key":"10.1124\/pharmrev.120.000072_bib196","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1007\/s11033-018-4231-7","article-title":"Aptamers that bind to the human complement component receptor hC5aR1 interfere with hC5aR1 interaction to its hC5a ligand","volume":"45","author":"Kumar","year":"2018","journal-title":"Mol Biol Rep"},{"key":"10.1124\/pharmrev.120.000072_bib197","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.omtm.2019.04.009","article-title":"Investigational RNAi therapeutic targeting C5 is efficacious in pre-clinical models of myasthenia gravis","volume":"13","author":"Kusner","year":"2019","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1124\/pharmrev.120.000072_bib198","doi-asserted-by":"crossref","first-page":"691","DOI":"10.4049\/jimmunol.100.4.691","article-title":"The demonstration in human serum of \u201cconglutinogen-activating factor\u201d and its effect on the third component of complement","volume":"100","author":"Lachmann","year":"1968","journal-title":"J Immunol"},{"key":"10.1124\/pharmrev.120.000072_bib199","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1084\/jem.115.1.63","article-title":"The localization of in vivo bound complement in tissue section","volume":"115","author":"Lachmann","year":"1962","journal-title":"J Exp Med"},{"key":"10.1124\/pharmrev.120.000072_bib200","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1084\/jem.131.4.643","article-title":"Reactive lysis: the complement-mediated lysis of unsensitized cells. II. The characterization of activated reactor as C56 and the participation of C8 and C9","volume":"131","author":"Lachmann","year":"1970","journal-title":"J Exp Med"},{"key":"10.1124\/pharmrev.120.000072_bib201","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1164\/ajrccm\/138.2.368","article-title":"Accentuated formation of the terminal C5b-9 complement complex in patient plasma precedes development of the adult respiratory distress syndrome","volume":"138","author":"Langlois","year":"1988","journal-title":"Am Rev Respir Dis"},{"key":"10.1124\/pharmrev.120.000072_bib202","doi-asserted-by":"crossref","first-page":"21301","DOI":"10.1074\/jbc.M400520200","article-title":"Disease-associated mutations in human mannose-binding lectin compromise oligomerisation and activity of the final protein","volume":"279","author":"Larsen","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1124\/pharmrev.120.000072_bib203","doi-asserted-by":"crossref","first-page":"108555","DOI":"10.1016\/j.clim.2020.108555","article-title":"Anti-complement C5 therapy with eculizumab in three cases of critical COVID-19","volume":"219","author":"Laurence","year":"2020","journal-title":"Clin Immunol"},{"key":"10.1124\/pharmrev.120.000072_bib204","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1042\/bst0310758","article-title":"Mannan-binding lectin (MBL) production from human plasma","volume":"31","author":"Laursen","year":"2003","journal-title":"Biochem Soc Trans"},{"key":"10.1124\/pharmrev.120.000072_bib205","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.2174\/156652412802480925","article-title":"Structure, function and control of complement C5 and its proteolytic fragments","volume":"12","author":"Laursen","year":"2012","journal-title":"Curr Mol Med"},{"key":"10.1124\/pharmrev.120.000072_bib206","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1038\/77046","article-title":"Gene-expression profile of the ageing brain in mice","volume":"25","author":"Lee","year":"2000","journal-title":"Nat Genet"},{"key":"10.1124\/pharmrev.120.000072_bib207","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1111\/bph.13730","article-title":"Pharmacological inhibition of complement C5a-C5a1 receptor signalling ameliorates disease pathology in the hSOD1G93A mouse model of amyotrophic lateral sclerosis","volume":"174","author":"Lee","year":"2017","journal-title":"Br J Pharmacol"},{"key":"10.1124\/pharmrev.120.000072_bib208","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1186\/s12974-018-1217-2","article-title":"Complement components are upregulated and correlate with disease progression in the TDP-43Q331K mouse model of amyotrophic lateral sclerosis","volume":"15","author":"Lee","year":"2018","journal-title":"J Neuroinflammation"},{"key":"10.1124\/pharmrev.120.000072_bib209","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1080\/14712598.2020.1725468","article-title":"Ravulizumab for the treatment of paroxysmal nocturnal hemoglobinuria","volume":"20","author":"Lee","year":"2020","journal-title":"Expert Opin Biol Ther"},{"key":"10.1124\/pharmrev.120.000072_bib210","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1182\/blood-2018-09-876136","article-title":"Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study","volume":"133","author":"Lee","year":"2019","journal-title":"Blood"},{"key":"10.1124\/pharmrev.120.000072_bib211","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1056\/NEJMoa1208981","article-title":"Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome","volume":"368","author":"Legendre","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1124\/pharmrev.120.000072_bib212","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.neuron.2018.09.017","article-title":"CD47 protects synapses from excess microglia-mediated pruning during development","volume":"100","author":"Lehrman","year":"2018","journal-title":"Neuron"},{"key":"10.1124\/pharmrev.120.000072_bib213","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/1471-2202-7-55","article-title":"Reduced neuronal cell death after experimental brain injury in mice lacking a functional alternative pathway of complement activation","volume":"7","author":"Leinhase","year":"2006","journal-title":"BMC Neurosci"},{"key":"10.1124\/pharmrev.120.000072_bib214","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1084\/jem.117.6.983","article-title":"Chromatographic resolution of the first component of human complement into three activities","volume":"117","author":"Lepow","year":"1963","journal-title":"J Exp Med"},{"key":"10.1124\/pharmrev.120.000072_bib215","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1586\/14779072.4.5.649","article-title":"The use of TP10, soluble complement receptor 1, in cardiopulmonary bypass","volume":"4","author":"Li","year":"2006","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"10.1124\/pharmrev.120.000072_bib216","doi-asserted-by":"crossref","first-page":"3339","DOI":"10.4049\/jimmunol.1900371","article-title":"The complement receptor C5aR2: a powerful modulator of innate and adaptive immunity","volume":"202","author":"Li","year":"2019","journal-title":"J Immunol"},{"key":"10.1124\/pharmrev.120.000072_bib217","doi-asserted-by":"crossref","first-page":"114156","DOI":"10.1016\/j.bcp.2020.114156","article-title":"Pharmacological characterisation of small molecule C5aR1 inhibitors in human cells reveals biased activities for signalling and function","volume":"180","author":"Li","year":"2020","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/pharmrev.120.000072_bib218","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1111\/j.1365-2249.2008.03700.x","article-title":"Mannose-binding lectin gene polymorphic variants predispose to the development of bronchopulmonary complications but have no influence on other clinical and laboratory symptoms or signs of common variable immunodeficiency","volume":"153","author":"Litzman","year":"2008","journal-title":"Clin Exp Immunol"},{"key":"10.1124\/pharmrev.120.000072_bib219","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1038\/s41594-018-0067-z","article-title":"Orthosteric and allosteric action of the C5a receptor antagonists","volume":"25","author":"Liu","year":"2018","journal-title":"Nat Struct Mol Biol"},{"key":"10.1124\/pharmrev.120.000072_bib220","doi-asserted-by":"crossref","first-page":"20991","DOI":"10.1074\/jbc.M111.226266","article-title":"Relationship between complement membrane attack complex, chemokine (C-C motif) ligand 2 (CCL2) and vascular endothelial growth factor in mouse model of laser-induced choroidal neovascularization","volume":"286","author":"Liu","year":"2011","journal-title":"J Biol Chem"},{"key":"10.1124\/pharmrev.120.000072_bib221","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.4049\/jimmunol.2000644","article-title":"COVID-19: complement, coagulation, and collateral damage","volume":"205","author":"Lo","year":"2020","journal-title":"J Immunol"},{"key":"10.1124\/pharmrev.120.000072_bib222","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1002\/JLB.3MIR0220-270R","article-title":"Complement: bridging the innate and adaptive immune systems in sterile inflammation","volume":"108","author":"Lo","year":"2020","journal-title":"J Leukoc Biol"},{"key":"10.1124\/pharmrev.120.000072_bib223","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1038\/s41467-017-00414-w","article-title":"Exploiting a novel conformational switch to control innate immunity mediated by complement protein C3a","volume":"8","author":"Lohman","year":"2017","journal-title":"Nat Commun"},{"key":"10.1124\/pharmrev.120.000072_bib224","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s00467-015-3076-8","article-title":"An international consensus approach to the management of atypical hemolytic uremic syndrome in children","volume":"31","author":"Loirat","year":"2016","journal-title":"Pediatr Nephrol"},{"key":"10.1124\/pharmrev.120.000072_bib225","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1002\/ajh.24278","article-title":"Impact of eculizumab treatment on paroxysmal nocturnal hemoglobinuria: a treatment versus no-treatment study","volume":"91","author":"Loschi","year":"2016","journal-title":"Am J Hematol"},{"key":"10.1124\/pharmrev.120.000072_bib226","first-page":"6","article-title":"Similarity in structure between C1q and the collectins as judged by electron microscopy","volume":"93","author":"Lu","year":"1993","journal-title":"Behring Inst Mitt"},{"key":"10.1124\/pharmrev.120.000072_bib227","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/j.cell.2016.04.001","article-title":"Progranulin deficiency promotes circuit-specific synaptic pruning by microglia via complement activation","volume":"165","author":"Lui","year":"2016","journal-title":"Cell"},{"key":"10.1124\/pharmrev.120.000072_bib228","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.semcdb.2017.11.022","article-title":"Complement components as promoters of immunological tolerance in dendritic cells","volume":"85","author":"Luque","year":"2019","journal-title":"Semin Cell Dev Biol"},{"key":"10.1124\/pharmrev.120.000072_bib229","doi-asserted-by":"crossref","first-page":"3365","DOI":"10.4049\/jimmunol.1500493","article-title":"Soluble collectin-12 (CL-12) is a pattern recognition molecule initiating complement activation via the alternative pathway","volume":"195","author":"Ma","year":"2015","journal-title":"J Immunol"},{"key":"10.1124\/pharmrev.120.000072_bib230","doi-asserted-by":"crossref","DOI":"10.1038\/emm.2017.51","article-title":"An overview of the synergy and crosstalk between pentraxins and collectins\/ficolins: their functional relevance in complement activation","volume":"49","author":"Ma","year":"2017","journal-title":"Exp Mol Med"},{"key":"10.1124\/pharmrev.120.000072_bib231","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1002\/art.34430","article-title":"Treatment of experimental arthritis models by targeting synovial endothelium with a neutralizing recombinant antibody to C5","volume":"64","author":"Macor","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1124\/pharmrev.120.000072_bib232","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1002\/ajh.25841","article-title":"Patients with paroxysmal nocturnal hemoglobinuria demonstrate a prothrombotic clotting phenotype which is improved by complement inhibition with eculizumab","volume":"95","author":"Macrae","year":"2020","journal-title":"Am J Hematol"},{"key":"10.1124\/pharmrev.120.000072_bib233","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1111\/imm.12489","article-title":"C5a alters blood-brain barrier integrity in a human in vitro model of systemic lupus erythematosus","volume":"146","author":"Mahajan","year":"2015","journal-title":"Immunology"},{"key":"10.1124\/pharmrev.120.000072_bib234","first-page":"305","article-title":"Structure, distribution, and functional role of protectin (CD59) in complement-susceptibility and in immunotherapy of human malignancies (Review)","volume":"13","author":"Maio","year":"1998","journal-title":"Int J Oncol"},{"key":"10.1124\/pharmrev.120.000072_bib235","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.immuni.2020.06.017","article-title":"Cytokine storms: understanding COVID-19","volume":"53","author":"Mangalmurti","year":"2020","journal-title":"Immunity"},{"key":"10.1124\/pharmrev.120.000072_bib236","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1016\/j.biocel.2009.04.005","article-title":"Complement component 5a (C5a)","volume":"41","author":"Manthey","year":"2009","journal-title":"Int J Biochem Cell Biol"},{"key":"10.1124\/pharmrev.120.000072_bib237","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.jneuroim.2014.09.005","article-title":"Elevation of the terminal complement activation products C5a and C5b-9 in ALS patient blood","volume":"276","author":"Mantovani","year":"2014","journal-title":"J Neuroimmunol"},{"key":"10.1124\/pharmrev.120.000072_bib238","doi-asserted-by":"crossref","first-page":"102836","DOI":"10.1016\/j.ebiom.2020.102836","article-title":"Targeting innate immunity by blocking CD14: novel approach to control inflammation and organ dysfunction in COVID-19 illness","volume":"57","author":"Martin","year":"2020","journal-title":"EBioMedicine"},{"key":"10.1124\/pharmrev.120.000072_bib239","doi-asserted-by":"crossref","first-page":"108450","DOI":"10.1016\/j.clim.2020.108450","article-title":"The first case of COVID-19 treated with the complement C3 inhibitor AMY-101","volume":"215","author":"Mastaglio","year":"2020","journal-title":"Clin Immunol"},{"key":"10.1124\/pharmrev.120.000072_bib240","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.it.2017.03.003","article-title":"Complement C3-targeted therapy: replacing long-held assertions with evidence-based discovery","volume":"38","author":"Mastellos","year":"2017","journal-title":"Trends Immunol"},{"key":"10.1124\/pharmrev.120.000072_bib241","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1038\/s41573-019-0031-6","article-title":"Clinical promise of next-generation complement therapeutics","volume":"18","author":"Mastellos","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"10.1124\/pharmrev.120.000072_bib242","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1084\/jem.176.6.1497","article-title":"Activation of the classical complement pathway by mannose-binding protein in association with a novel C1s-like serine protease","volume":"176","author":"Matsushita","year":"1992","journal-title":"J Exp Med"},{"key":"10.1124\/pharmrev.120.000072_bib243","doi-asserted-by":"crossref","first-page":"2950","DOI":"10.4049\/jimmunol.176.5.2950","article-title":"Evidence that complement protein C1q interacts with C-reactive protein through its globular head region","volume":"176","author":"McGrath","year":"2006","journal-title":"J Immunol"},{"key":"10.1124\/pharmrev.120.000072_bib244","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s40265-019-01068-2","article-title":"Ravulizumab: first global approval","volume":"79","author":"McKeage","year":"2019","journal-title":"Drugs"},{"key":"10.1124\/pharmrev.120.000072_bib245","doi-asserted-by":"crossref","first-page":"5446","DOI":"10.4049\/jimmunol.1403012","article-title":"A new approach for the treatment of arthritis in mice with a novel conjugate of an anti-C5aR1 antibody and C5 small interfering RNA","volume":"194","author":"Mehta","year":"2015","journal-title":"J Immunol"},{"key":"10.1124\/pharmrev.120.000072_bib246","first-page":"149","article-title":"Protectin (CD59) - complement lysis inhibitor and prototype domain in a new protein superfamily","volume":"2","author":"Meri","year":"1994","journal-title":"Immunologist"},{"key":"10.1124\/pharmrev.120.000072_bib247","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.ejim.2013.05.009","article-title":"Complement activation in diseases presenting with thrombotic microangiopathy","volume":"24","author":"Meri","year":"2013","journal-title":"Eur J Intern Med"},{"key":"10.1124\/pharmrev.120.000072_bib248","doi-asserted-by":"crossref","first-page":"262","DOI":"10.3389\/fimmu.2015.00262","article-title":"Complement system Part I - molecular mechanisms of activation and regulation","volume":"6","author":"Merle","year":"2015","journal-title":"Front Immunol"},{"key":"10.1124\/pharmrev.120.000072_bib249","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1182\/blood-2015-09-672139","article-title":"Complement activation in antiphospholipid syndrome and its inhibition to prevent rethrombosis after arterial surgery","volume":"127","author":"Meroni","year":"2016","journal-title":"Blood"},{"key":"10.1124\/pharmrev.120.000072_bib250","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/s41584-020-0474-5","article-title":"Emerging evidence of a COVID-19 thrombotic syndrome has treatment implications","volume":"16","author":"Merrill","year":"2020","journal-title":"Nat Rev Rheumatol"},{"key":"10.1124\/pharmrev.120.000072_bib251","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/j.imbio.2011.12.004","article-title":"H-ficolin (ficolin-3) concentrations and FCN3 gene polymorphism in neonates","volume":"217","author":"Michalski","year":"2012","journal-title":"Immunobiology"},{"key":"10.1124\/pharmrev.120.000072_bib252","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1681\/ASN.2015070745","article-title":"Moss-produced, glycosylation-optimized human factor H for therapeutic application in complement disorders","volume":"28","author":"Michelfelder","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"10.1124\/pharmrev.120.000072_bib253","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1126\/science.aaj2067","article-title":"Local amplifiers of IL-4R\u03b1-mediated macrophage activation promote repair in lung and liver","volume":"356","author":"Minutti","year":"2017","journal-title":"Science"},{"key":"10.1124\/pharmrev.120.000072_bib254","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1002\/1873-3468.13881","article-title":"Complement in sepsis-when science meets clinics","volume":"594","author":"Mollnes","year":"2020","journal-title":"FEBS Lett"},{"key":"10.1124\/pharmrev.120.000072_bib255","doi-asserted-by":"crossref","first-page":"3838","DOI":"10.1016\/j.molimm.2007.06.150","article-title":"Complement analysis in the 21st century","volume":"44","author":"Mollnes","year":"2007","journal-title":"Mol Immunol"},{"key":"10.1124\/pharmrev.120.000072_bib256","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/j.1365-3083.1985.tb01870.x","article-title":"Monoclonal antibodies recognizing a neoantigen of poly(C9) detect the human terminal complement complex in tissue and plasma","volume":"22","author":"Mollnes","year":"1985","journal-title":"Scand J Immunol"},{"issue":"Suppl 3","key":"10.1124\/pharmrev.120.000072_bib257","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/ajt.14584","article-title":"Antibody-mediated rejection: new approaches in prevention and management","volume":"18","author":"Montgomery","year":"2018","journal-title":"Am J Transplant"},{"key":"10.1124\/pharmrev.120.000072_bib258","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1042\/bj2310205","article-title":"The recovery of human polymorphonuclear leucocytes from sublytic complement attack is mediated by changes in intracellular free calcium","volume":"231","author":"Morgan","year":"1985","journal-title":"Biochem J"},{"key":"10.1124\/pharmrev.120.000072_bib259","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1084\/jem.111.2.201","article-title":"Isolation and characterization of two beta1-glycoproteins of human serum","volume":"111","author":"Muller-Eberhard","year":"1960","journal-title":"J Exp Med"},{"key":"10.1124\/pharmrev.120.000072_bib260","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1097\/ALN.0000000000003149","article-title":"Neutralizing complement C5a protects mice with pneumococcal pulmonary sepsis","volume":"132","author":"M\u00fcller-Redetzky","year":"2020","journal-title":"Anesthesiology"},{"key":"10.1124\/pharmrev.120.000072_bib261","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.1056\/NEJMoa0900381","article-title":"Immunodeficiency associated with FCN3 mutation and ficolin-3 deficiency","volume":"360","author":"Munthe-Fog","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1124\/pharmrev.120.000072_bib262","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1006679","article-title":"COLEC10 is mutated in 3MC patients and regulates early craniofacial development","volume":"13","author":"Munye","year":"2017","journal-title":"PLoS Genet"},{"key":"10.1124\/pharmrev.120.000072_bib263","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/978-981-15-1580-4_4","article-title":"Collectins: innate immune pattern recognition molecules","volume":"1204","author":"Murugaiah","year":"2020","journal-title":"Adv Exp Med Biol"},{"key":"10.1124\/pharmrev.120.000072_bib264","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1111\/ajt.15785","article-title":"Successful simultaneous liver-kidney transplantation for renal failure associated with hereditary complement C3 deficiency","volume":"20","author":"Nayagam","year":"2020","journal-title":"Am J Transplant"},{"key":"10.1124\/pharmrev.120.000072_bib265","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1038\/nrd3229","article-title":"Development trends for human monoclonal antibody therapeutics","volume":"9","author":"Nelson","year":"2010","journal-title":"Nat Rev Drug Discov"},{"key":"10.1124\/pharmrev.120.000072_bib266","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1556\/EuJMI.2.2012.2.2","article-title":"The complement system: history, pathways, cascade and inhibitors","volume":"2","author":"Nesargikar","year":"2012","journal-title":"Eur J Microbiol Immunol (Bp)"},{"key":"10.1124\/pharmrev.120.000072_bib267","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.smim.2016.06.002","article-title":"Complement inhibition in C3 glomerulopathy","volume":"28","author":"Nester","year":"2016","journal-title":"Semin Immunol"},{"key":"10.1124\/pharmrev.120.000072_bib268","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/S0140-6736(01)05776-2","article-title":"Deficiency of mannose-binding lectin and burden of infection in children with malignancy: a prospective study","volume":"358","author":"Neth","year":"2001","journal-title":"Lancet"},{"key":"10.1124\/pharmrev.120.000072_bib269","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1038\/ki.2015.233","article-title":"An extended mini-complement factor H molecule ameliorates experimental C3 glomerulopathy","volume":"88","author":"Nichols","year":"2015","journal-title":"Kidney Int"},{"key":"10.1124\/pharmrev.120.000072_bib270","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1007\/s12185-016-2065-4","article-title":"Interim analysis of post-marketing surveillance of eculizumab for paroxysmal nocturnal hemoglobinuria in Japan","volume":"104","author":"Ninomiya","year":"2016","journal-title":"Int J Hematol"},{"key":"10.1124\/pharmrev.120.000072_bib271","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1056\/NEJMoa1311084","article-title":"Genetic variants in C5 and poor response to eculizumab","volume":"370","author":"Nishimura","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1124\/pharmrev.120.000072_bib272","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.3201\/eid2408.180228","article-title":"Fatal nongroupable Neisseria meningitidis disease in vaccinated patient receiving eculizumab","volume":"24","author":"Nolfi-Donegan","year":"2018","journal-title":"Emerg Infect Dis"},{"key":"10.1124\/pharmrev.120.000072_bib273","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.kint.2020.05.013","article-title":"The case of complement activation in COVID-19 multiorgan impact","volume":"98","author":"Noris","year":"2020","journal-title":"Kidney Int"},{"key":"10.1124\/pharmrev.120.000072_bib274","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S0165-5728(00)00291-5","article-title":"The C5a complement activation peptide increases IL-1beta and IL-6 release from amyloid-beta primed human monocytes: implications for Alzheimer\u2019s disease","volume":"109","author":"O\u2019Barr","year":"2000","journal-title":"J Neuroimmunol"},{"key":"10.1124\/pharmrev.120.000072_bib275","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1159\/000356980","article-title":"Myeloperoxidase directs properdin-mediated complement activation","volume":"6","author":"O\u2019Flynn","year":"2014","journal-title":"J Innate Immun"},{"key":"10.1124\/pharmrev.120.000072_bib276","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1097\/TP.0000000000001842","article-title":"Proximal blockade of complement: a \u201cneoclassical\u201d approach to prevent antibody-mediated rejection","volume":"101","author":"O\u2019Neill","year":"2017","journal-title":"Transplantation"},{"key":"10.1124\/pharmrev.120.000072_bib277","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1056\/NEJMoa033122","article-title":"Mannose-binding lectin variant alleles and the risk of arterial thrombosis in systemic lupus erythematosus","volume":"351","author":"\u00d8hlenschlaeger","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1124\/pharmrev.120.000072_bib278","doi-asserted-by":"crossref","first-page":"857","DOI":"10.4049\/jimmunol.1501717","article-title":"MASP-1 and MASP-2 do not activate pro-factor D in resting human blood, whereas MASP-3 is a potential activator: kinetic analysis involving specific MASP-1 and MASP-2 inhibitors","volume":"196","author":"Oroszl\u00e1n","year":"2016","journal-title":"J Immunol"},{"key":"10.1124\/pharmrev.120.000072_bib279","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1056\/NEJMoa1615887","article-title":"CD55 deficiency, early-onset protein-losing enteropathy, and thrombosis","volume":"377","author":"Ozen","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1124\/pharmrev.120.000072_bib280","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0225417","article-title":"C5aR agonist enhances phagocytosis of fibrillar and non-fibrillar A\u03b2 amyloid and preserves memory in a mouse model of familial Alzheimer\u2019s disease","volume":"14","author":"Panayiotou","year":"2019","journal-title":"PLoS One"},{"key":"10.1124\/pharmrev.120.000072_bib281","doi-asserted-by":"crossref","first-page":"3326","DOI":"10.4049\/jimmunol.1601864","article-title":"Structural implications for the formation and function of the complement effector protein iC3b","volume":"198","author":"Papanastasiou","year":"2017","journal-title":"J Immunol"},{"key":"10.1124\/pharmrev.120.000072_bib282","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.3389\/fimmu.2019.01007","article-title":"The challenges and promise of complement therapeutics for ocular diseases","volume":"10","author":"Park","year":"2019","journal-title":"Front Immunol"},{"key":"10.1124\/pharmrev.120.000072_bib283","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(09)60001-5","article-title":"Eculizumab for paroxysmal nocturnal haemoglobinuria","volume":"373","author":"Parker","year":"2009","journal-title":"Lancet"},{"key":"10.1124\/pharmrev.120.000072_bib284","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.nbd.2019.03.003","article-title":"Revisiting the role of the innate immune complement system in ALS","volume":"127","author":"Parker","year":"2019","journal-title":"Neurobiol Dis"},{"key":"10.1124\/pharmrev.120.000072_bib285","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/S0003-4975(01)03029-6","article-title":"Endothelial damage during myocardial preservation and storage","volume":"73","author":"Parolari","year":"2002","journal-title":"Ann Thorac Surg"},{"key":"10.1124\/pharmrev.120.000072_bib286","doi-asserted-by":"crossref","first-page":"3680","DOI":"10.1096\/fj.11-202382","article-title":"Generation of complement component C5a by ischemic neurons promotes neuronal apoptosis","volume":"26","author":"Pavlovski","year":"2012","journal-title":"FASEB J"},{"key":"10.1124\/pharmrev.120.000072_bib287","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1146\/annurev.iy.04.040186.001311","article-title":"Molecular immunobiology of complement biosynthesis: a model of single-cell control of effector-inhibitor balance","volume":"4","author":"Perlmutter","year":"1986","journal-title":"Annu Rev Immunol"},{"key":"10.1124\/pharmrev.120.000072_bib288","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s10875-006-9037-z","article-title":"Phase I safety, tolerability, and pharmacokinetic study of recombinant human mannan-binding lectin","volume":"26","author":"Petersen","year":"2006","journal-title":"J Clin Immunol"},{"key":"10.1124\/pharmrev.120.000072_bib289","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/S0140-6736(01)05785-3","article-title":"Association between deficiency of mannose-binding lectin and severe infections after chemotherapy","volume":"358","author":"Peterslund","year":"2001","journal-title":"Lancet"},{"key":"10.1124\/pharmrev.120.000072_bib290","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1111\/j.2164-0947.1955.tb02817.x","article-title":"The properdin system","volume":"17","author":"Pillemer","year":"1955","journal-title":"Trans N Y Acad Sci"},{"key":"10.1124\/pharmrev.120.000072_bib291","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1126\/science.120.3112.279","article-title":"The properdin system and immunity. I. Demonstration and isolation of a new serum protein, properdin, and its role in immune phenomena","volume":"120","author":"Pillemer","year":"1954","journal-title":"Science"},{"key":"10.1124\/pharmrev.120.000072_bib292","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1056\/NEJMoa1900866","article-title":"Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder","volume":"381","author":"Pittock","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1124\/pharmrev.120.000072_bib293","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1084\/jem.151.2.301","article-title":"Membrane attack complex of complement: a structural analysis of its assembly","volume":"151","author":"Podack","year":"1980","journal-title":"J Exp Med"},{"key":"10.1124\/pharmrev.120.000072_bib294","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1111\/j.1365-3083.2008.02089.x","article-title":"Complement component c1q and anti-c1q antibodies in theory and in clinical practice","volume":"67","author":"Potlukova","year":"2008","journal-title":"Scand J Immunol"},{"key":"10.1124\/pharmrev.120.000072_bib295","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/j.molimm.2003.10.013","article-title":"Differential substrate and inhibitor profiles for human MASP-1 and MASP-2","volume":"40","author":"Presanis","year":"2004","journal-title":"Mol Immunol"},{"key":"10.1124\/pharmrev.120.000072_bib296","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.molimm.2018.06.001","article-title":"Complement analysis in the era of targeted therapeutics","volume":"102","author":"Proh\u00e1szka","year":"2018","journal-title":"Mol Immunol"},{"key":"10.1124\/pharmrev.120.000072_bib297","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1038\/s41591-020-1021-2","article-title":"Immune complement and coagulation dysfunction in adverse outcomes of SARS-CoV-2 infection","volume":"26","author":"Ramlall","year":"2020","journal-title":"Nat Med"},{"key":"10.1124\/pharmrev.120.000072_bib298","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2013-003573","article-title":"A systematic review of eculizumab for atypical haemolytic uraemic syndrome (aHUS)","volume":"3","author":"Rathbone","year":"2013","journal-title":"BMJ Open"},{"key":"10.1124\/pharmrev.120.000072_bib299","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1002\/jor.21561","article-title":"C5aR-antagonist significantly reduces the deleterious effect of a blunt chest trauma on fracture healing","volume":"30","author":"Recknagel","year":"2012","journal-title":"J Orthop Res"},{"key":"10.1124\/pharmrev.120.000072_bib300","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1016\/j.vaccine.2018.03.087","article-title":"A rare case of septic shock due to Neisseria meningitidis serogroup B infection despite prior vaccination in a young adult with paroxysmal nocturnal haemoglobinuria receiving eculizumab","volume":"36","author":"Reher","year":"2018","journal-title":"Vaccine"},{"key":"10.1124\/pharmrev.120.000072_bib301","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/1742-2094-6-35","article-title":"Expression of complement system components during aging and amyloid deposition in APP transgenic mice","volume":"6","author":"Reichwald","year":"2009","journal-title":"J Neuroinflammation"},{"key":"10.1124\/pharmrev.120.000072_bib302","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1042\/bj1300749","article-title":"Isolation and characterization of C1q, a subcomponent of the first component of complement, from human and rabbit sera","volume":"130","author":"Reid","year":"1972","journal-title":"Biochem J"},{"key":"10.1124\/pharmrev.120.000072_bib303","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.3389\/fphar.2019.01381","article-title":"Intravitreal therapy against the complement factor C5 prevents retinal degeneration in an experimental autoimmune glaucoma model","volume":"10","author":"Reinehr","year":"2019","journal-title":"Front Pharmacol"},{"key":"10.1124\/pharmrev.120.000072_bib304","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/s41577-019-0168-x","article-title":"New insights into the immune functions of complement","volume":"19","author":"Reis","year":"2019","journal-title":"Nat Rev Immunol"},{"key":"10.1124\/pharmrev.120.000072_bib305","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/j.1365-3083.2006.01729.x","article-title":"Clinical aspects and molecular basis of primary deficiencies of complement component C3 and its regulatory proteins factor I and factor H","volume":"63","author":"Reis","year":"2006","journal-title":"Scand J Immunol"},{"key":"10.1124\/pharmrev.120.000072_bib306","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.neulet.2016.02.025","article-title":"Site-targeted complement inhibition by a complement receptor 2-conjugated inhibitor (mTT30) ameliorates post-injury neuropathology in mouse brains","volume":"617","author":"Rich","year":"2016","journal-title":"Neurosci Lett"},{"key":"10.1124\/pharmrev.120.000072_bib307","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.molimm.2017.05.013","article-title":"Complement in clinical medicine: clinical trials, case reports and therapy monitoring","volume":"89","author":"Ricklin","year":"2017","journal-title":"Mol Immunol"},{"key":"10.1124\/pharmrev.120.000072_bib308","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1038\/ni.1923","article-title":"Complement: a key system for immune surveillance and homeostasis","volume":"11","author":"Ricklin","year":"2010","journal-title":"Nat Immunol"},{"key":"10.1124\/pharmrev.120.000072_bib309","doi-asserted-by":"crossref","first-page":"3831","DOI":"10.4049\/jimmunol.1203487","article-title":"Complement in immune and inflammatory disorders: pathophysiological mechanisms","volume":"190","author":"Ricklin","year":"2013","journal-title":"J Immunol"},{"key":"10.1124\/pharmrev.120.000072_bib310","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/nrneph.2017.156","article-title":"The renaissance of complement therapeutics","volume":"14","author":"Ricklin","year":"2018","journal-title":"Nat Rev Nephrol"},{"key":"10.1124\/pharmrev.120.000072_bib311","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.3389\/fimmu.2019.01157","article-title":"Anti-complement treatment for paroxysmal nocturnal hemoglobinuria: time for proximal complement inhibition? A position paper from the SAAWP of the EBMT","volume":"10","author":"Risitano","year":"2019","journal-title":"Front Immunol"},{"key":"10.1124\/pharmrev.120.000072_bib312","doi-asserted-by":"crossref","first-page":"6307","DOI":"10.1182\/blood-2011-12-398792","article-title":"The complement receptor 2\/factor H fusion protein TT30 protects paroxysmal nocturnal hemoglobinuria erythrocytes from complement-mediated hemolysis and C3 fragment","volume":"119","author":"Risitano","year":"2012","journal-title":"Blood"},{"key":"10.1124\/pharmrev.120.000072_bib313","doi-asserted-by":"crossref","first-page":"959","DOI":"10.3390\/molecules23040959","article-title":"Using peptidomimetics and constrained peptides as valuable tools for inhibiting Protein\u2212Protein interactions","volume":"23","author":"Robertson","year":"2018","journal-title":"Molecules"},{"key":"10.1124\/pharmrev.120.000072_bib314","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1016\/j.ekir.2019.07.016","article-title":"Eculizumab safety: five-year experience from the global atypical hemolytic uremic syndrome registry","volume":"4","author":"Rondeau","year":"2019","journal-title":"Kidney Int Rep"},{"key":"10.1124\/pharmrev.120.000072_bib315","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/ng.757","article-title":"Mutations in lectin complement pathway genes COLEC11 and MASP1 cause 3MC syndrome","volume":"43","author":"Rooryck","year":"2011","journal-title":"Nat Genet"},{"key":"10.1124\/pharmrev.120.000072_bib316","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1681\/ASN.2005090923","article-title":"Glomerular activation of the lectin pathway of complement in IgA nephropathy is associated with more severe renal disease","volume":"17","author":"Roos","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"10.1124\/pharmrev.120.000072_bib317","doi-asserted-by":"crossref","first-page":"40880","DOI":"10.1074\/jbc.M105934200","article-title":"Substrate specificities of recombinant mannan-binding lectin-associated serine proteases-1 and -2","volume":"276","author":"Rossi","year":"2001","journal-title":"J Biol Chem"},{"key":"10.1124\/pharmrev.120.000072_bib318","doi-asserted-by":"crossref","first-page":"3885","DOI":"10.1182\/blood-2009-01-196329","article-title":"Long-term efficacy of the complement inhibitor eculizumab in cold agglutinin disease","volume":"113","author":"R\u00f6th","year":"2009","journal-title":"Blood"},{"key":"10.1124\/pharmrev.120.000072_bib319","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1182\/blood.2019003399","article-title":"The complement C5 inhibitor crovalimab in paroxysmal nocturnal hemoglobinuria","volume":"135","author":"R\u00f6th","year":"2020","journal-title":"Blood"},{"key":"10.1124\/pharmrev.120.000072_bib320","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1159\/000075690","article-title":"The role of complement in the antiphospholipid syndrome","volume":"7","author":"Salmon","year":"2004","journal-title":"Curr Dir Autoimmun"},{"key":"10.1124\/pharmrev.120.000072_bib321","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1093\/intimm\/6.4.665","article-title":"Molecular characterization of a novel serine protease involved in activation of the complement system by mannose-binding protein","volume":"6","author":"Sato","year":"1994","journal-title":"Int Immunol"},{"key":"10.1124\/pharmrev.120.000072_bib322","doi-asserted-by":"crossref","first-page":"35237","DOI":"10.1074\/jbc.R114.619304","article-title":"Complexity of danger: the diverse nature of damage-associated molecular patterns","volume":"289","author":"Schaefer","year":"2014","journal-title":"J Biol Chem"},{"key":"10.1124\/pharmrev.120.000072_bib323","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.neuron.2012.03.026","article-title":"Microglia sculpt postnatal neural circuits in an activity and complement-dependent manner","volume":"74","author":"Schafer","year":"2012","journal-title":"Neuron"},{"key":"10.1124\/pharmrev.120.000072_bib324","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.nbd.2017.10.012","article-title":"Status epilepticus triggers long-lasting activation of complement C1q-C3 signaling in the hippocampus that correlates with seizure frequency in experimental epilepsy","volume":"109","author":"Schartz","year":"2018","journal-title":"Neurobiol Dis"},{"key":"10.1124\/pharmrev.120.000072_bib325","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1016\/j.imbio.2013.04.021","article-title":"Primary complement C5 deficiencies - molecular characterization and clinical review of two families","volume":"218","author":"Schejbel","year":"2013","journal-title":"Immunobiology"},{"key":"10.1124\/pharmrev.120.000072_bib326","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.clim.2009.02.008","article-title":"Properdin deficiency associated with recurrent otitis media and pneumonia, and identification of male carrier with Klinefelter syndrome","volume":"131","author":"Schejbel","year":"2009","journal-title":"Clin Immunol"},{"key":"10.1124\/pharmrev.120.000072_bib327","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1136\/gut.2010.226027","article-title":"Congenital H-ficolin deficiency in premature infants with severe necrotising enterocolitis","volume":"60","author":"Schlapbach","year":"2011","journal-title":"Gut"},{"key":"10.1124\/pharmrev.120.000072_bib328","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1111\/imr.12475","article-title":"Protection of host cells by complement regulators","volume":"274","author":"Schmidt","year":"2016","journal-title":"Immunol Rev"},{"key":"10.1124\/pharmrev.120.000072_bib329","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/j.immuni.2013.11.011","article-title":"S100A8-S100A9 protein complex mediates psoriasis by regulating the expression of complement factor C3","volume":"39","author":"Schonthaler","year":"2013","journal-title":"Immunity"},{"key":"10.1124\/pharmrev.120.000072_bib330","doi-asserted-by":"crossref","first-page":"3142","DOI":"10.1016\/j.molimm.2008.03.010","article-title":"Dynamic structural changes during complement C3 activation analyzed by hydrogen\/deuterium exchange mass spectrometry","volume":"45","author":"Schuster","year":"2008","journal-title":"Mol Immunol"},{"key":"10.1124\/pharmrev.120.000072_bib331","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.jim.2004.11.016","article-title":"Functional analysis of the classical, alternative, and MBL pathways of the complement system: standardization and validation of a simple ELISA","volume":"296","author":"Seelen","year":"2005","journal-title":"J Immunol Methods"},{"key":"10.1124\/pharmrev.120.000072_bib332","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1038\/nature16549","article-title":"Schizophrenia risk from complex variation of complement component 4","volume":"530","author":"Sekar","year":"2016","journal-title":"Nature"},{"key":"10.1124\/pharmrev.120.000072_bib333","doi-asserted-by":"crossref","first-page":"317","DOI":"10.5603\/PJNNS.a2019.0049","article-title":"Novel emerging treatments for NMOSD","volume":"53","author":"Selmaj","year":"2019","journal-title":"Neurol Neurochir Pol"},{"key":"10.1124\/pharmrev.120.000072_bib334","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.jneuroim.2004.06.003","article-title":"Complement C3 and C5 play critical roles in traumatic brain cryoinjury: blocking effects on neutrophil extravasation by C5a receptor antagonist","volume":"155","author":"Sewell","year":"2004","journal-title":"J Neuroimmunol"},{"key":"10.1124\/pharmrev.120.000072_bib335","doi-asserted-by":"crossref","first-page":"4015","DOI":"10.1182\/blood-2014-02-556027","article-title":"TNT003, an inhibitor of the serine protease C1s, prevents complement activation induced by cold agglutinins","volume":"123","author":"Shi","year":"2014","journal-title":"Blood"},{"key":"10.1124\/pharmrev.120.000072_bib336","doi-asserted-by":"crossref","first-page":"eaaf6295","DOI":"10.1126\/scitranslmed.aaf6295","article-title":"Complement C3 deficiency protects against neurodegeneration in aged plaque-rich APP\/PS1 mice","volume":"9","author":"Shi","year":"2017","journal-title":"Sci Transl Med"},{"key":"10.1124\/pharmrev.120.000072_bib337","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/j.imbio.2016.06.011","article-title":"Complement research in the 18th-21st centuries: progress comes with new technology","volume":"221","author":"Sim","year":"2016","journal-title":"Immunobiology"},{"key":"10.1124\/pharmrev.120.000072_bib338","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1159\/000163873","article-title":"Complement C3 deficiency: human, animal, and experimental models","volume":"62","author":"Singer","year":"1994","journal-title":"Pathobiology"},{"key":"10.1124\/pharmrev.120.000072_bib339","first-page":"1247","article-title":"Differential expression of individual complement regulators in the brain and choroid plexus","volume":"79","author":"Singhrao","year":"1999","journal-title":"Lab Invest"},{"key":"10.1124\/pharmrev.120.000072_bib340","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.ajhg.2010.09.018","article-title":"MASP1 mutations in patients with facial, umbilical, coccygeal, and auditory findings of Carnevale, Malpuech, OSA, and Michels syndromes","volume":"87","author":"Sirmaci","year":"2010","journal-title":"Am J Hum Genet"},{"key":"10.1124\/pharmrev.120.000072_bib341","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.it.2008.11.003","article-title":"Complement activation and inhibition: a delicate balance","volume":"30","author":"Sj\u00f6berg","year":"2009","journal-title":"Trends Immunol"},{"key":"10.1124\/pharmrev.120.000072_bib342","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.molimm.2005.06.025","article-title":"Complement deficiency and disease: an update","volume":"43","author":"Sj\u00f6holm","year":"2006","journal-title":"Mol Immunol"},{"key":"10.1124\/pharmrev.120.000072_bib343","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJM198807073190106","article-title":"Dysfunctional properdin in a Dutch family with meningococcal disease","volume":"319","author":"Sj\u00f6holm","year":"1988","journal-title":"N Engl J Med"},{"key":"10.1124\/pharmrev.120.000072_bib344","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1128\/br.21.4.273-294.1957","article-title":"Antimicrobial factors of normal tissues and fluids","volume":"21","author":"Skarnes","year":"1957","journal-title":"Bacteriol Rev"},{"key":"10.1124\/pharmrev.120.000072_bib345","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1016\/j.molimm.2011.05.001","article-title":"Complement deficiency states and associated infections","volume":"48","author":"Skattum","year":"2011","journal-title":"Mol Immunol"},{"key":"10.1124\/pharmrev.120.000072_bib346","doi-asserted-by":"crossref","first-page":"8234","DOI":"10.1074\/jbc.M109.065805","article-title":"A novel mannose-binding lectin\/ficolin-associated protein is highly expressed in heart and skeletal muscle tissues and inhibits complement activation","volume":"285","author":"Skjoedt","year":"2010","journal-title":"J Biol Chem"},{"key":"10.1124\/pharmrev.120.000072_bib347","doi-asserted-by":"crossref","first-page":"32913","DOI":"10.1074\/jbc.M112.386680","article-title":"Crystal structure and functional characterization of the complement regulator mannose-binding lectin (MBL)\/ficolin-associated protein-1 (MAP-1)","volume":"287","author":"Skjoedt","year":"2012","journal-title":"J Biol Chem"},{"key":"10.1124\/pharmrev.120.000072_bib348","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1056\/NEJMc1306326","article-title":"Deficiency in complement factor B","volume":"369","author":"Slade","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1124\/pharmrev.120.000072_bib349","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/bjh.15790","article-title":"Eculizumab in paroxysmal nocturnal haemoglobinuria and atypical haemolytic uraemic syndrome: 10-year pharmacovigilance analysis","volume":"185","author":"Soci\u00e9","year":"2019","journal-title":"Br J Haematol"},{"key":"10.1124\/pharmrev.120.000072_bib350","first-page":"3950","article-title":"COVID-19, microangiopathy, hemostatic activation, and complement","volume":"130","author":"Song","year":"2020","journal-title":"J Clin Invest"},{"key":"10.1124\/pharmrev.120.000072_bib351","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1038\/sj.bjp.0706286","article-title":"APT070 (Mirococept), a membrane-localised complement inhibitor, inhibits inflammatory responses that follow intestinal ischaemia and reperfusion injury","volume":"145","author":"Souza","year":"2005","journal-title":"Br J Pharmacol"},{"key":"10.1124\/pharmrev.120.000072_bib352","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.molimm.2003.10.017","article-title":"ScFv-mediated in vivo targeting of DAF to erythrocytes inhibits lysis by complement","volume":"40","author":"Spitzer","year":"2004","journal-title":"Mol Immunol"},{"key":"10.1124\/pharmrev.120.000072_bib353","doi-asserted-by":"crossref","first-page":"4865","DOI":"10.1182\/blood-2005-07-2820","article-title":"Deficient alternative complement pathway activation due to factor D deficiency by 2 novel mutations in the complement factor D gene in a family with meningococcal infections","volume":"107","author":"Sprong","year":"2006","journal-title":"Blood"},{"key":"10.1124\/pharmrev.120.000072_bib354","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.nbd.2011.01.002","article-title":"Innate and adaptive immunity in amyotrophic lateral sclerosis: evidence of complement activation","volume":"42","author":"Sta","year":"2011","journal-title":"Neurobiol Dis"},{"key":"10.1124\/pharmrev.120.000072_bib355","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1002\/j.2326-5205.1989.tb00023.x","article-title":"Successful plasma infusion treatment of a patient with C2 deficiency and systemic lupus erythematosus: clinical experience over forty-five months","volume":"32","author":"Steinsson","year":"1989","journal-title":"Arthritis Rheum"},{"key":"10.1124\/pharmrev.120.000072_bib356","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1056\/NEJMoa022836","article-title":"Inherited deficiency of mannan-binding lectin-associated serine protease 2","volume":"349","author":"Stengaard-Pedersen","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1124\/pharmrev.120.000072_bib357","doi-asserted-by":"crossref","DOI":"10.1177\/2040620719874728","article-title":"Ravulizumab: a novel C5 inhibitor for the treatment of paroxysmal nocturnal hemoglobinuria","volume":"10","author":"Stern","year":"2019","journal-title":"Ther Adv Hematol"},{"key":"10.1124\/pharmrev.120.000072_bib358","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/j.cell.2007.10.036","article-title":"The classical complement cascade mediates CNS synapse elimination","volume":"131","author":"Stevens","year":"2007","journal-title":"Cell"},{"key":"10.1124\/pharmrev.120.000072_bib359","doi-asserted-by":"crossref","first-page":"3481","DOI":"10.4049\/jimmunol.162.6.3481","article-title":"Two constituents of the initiation complex of the mannan-binding lectin activation pathway of complement are encoded by a single structural gene","volume":"162","author":"Stover","year":"1999","journal-title":"J Immunol"},{"key":"10.1124\/pharmrev.120.000072_bib360","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1681\/ASN.2011050464","article-title":"The pathophysiology of IgA nephropathy","volume":"22","author":"Suzuki","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"10.1124\/pharmrev.120.000072_bib361","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1159\/000184699","article-title":"Diseases associated with the low copy number of the C4B gene encoding C4, the fourth component of complement","volume":"123","author":"Szil\u00e1gyi","year":"2008","journal-title":"Cytogenet Genome Res"},{"key":"10.1124\/pharmrev.120.000072_bib362","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.molimm.2017.05.024","article-title":"Demyelination, strokes, and eculizumab: lessons from the congenital CD59 gene mutations","volume":"89","author":"Tabib","year":"2017","journal-title":"Mol Immunol"},{"key":"10.1124\/pharmrev.120.000072_bib363","doi-asserted-by":"crossref","first-page":"5764","DOI":"10.1073\/pnas.77.10.5764","article-title":"Evidence for presence of an internal thiolester bond in third component of human complement","volume":"77","author":"Tack","year":"1980","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/pharmrev.120.000072_bib364","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/0092-8674(93)90250-T","article-title":"Deficiency of the GPI anchor caused by a somatic mutation of the PIG-A gene in paroxysmal nocturnal hemoglobinuria","volume":"73","author":"Takeda","year":"1993","journal-title":"Cell"},{"key":"10.1124\/pharmrev.120.000072_bib365","doi-asserted-by":"crossref","first-page":"51","DOI":"10.3109\/08830189309051171","article-title":"Inherited deficiencies of the terminal complement components","volume":"10","author":"Tedesco","year":"1993","journal-title":"Int Rev Immunol"},{"key":"10.1124\/pharmrev.120.000072_bib366","doi-asserted-by":"crossref","first-page":"306","DOI":"10.4049\/jimmunol.1901068","article-title":"Complement-mediated events in Alzheimer\u2019s disease: mechanisms and potential therapeutic targets","volume":"204","author":"Tenner","year":"2020","journal-title":"J Immunol"},{"key":"10.1124\/pharmrev.120.000072_bib367","doi-asserted-by":"crossref","first-page":"13923","DOI":"10.1016\/S0021-9258(18)80088-6","article-title":"Human pulmonary surfactant protein (SP-A), a protein structurally homologous to C1q, can enhance FcR- and CR1-mediated phagocytosis","volume":"264","author":"Tenner","year":"1989","journal-title":"J Biol Chem"},{"key":"10.1124\/pharmrev.120.000072_bib368","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.molimm.2018.06.264","article-title":"New tricks for an ancient system: physiological and pathological roles of complement in the CNS","volume":"102","author":"Tenner","year":"2018","journal-title":"Mol Immunol"},{"key":"10.1124\/pharmrev.120.000072_bib369","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1038\/386506a0","article-title":"A second serine protease associated with mannan-binding lectin that activates complement","volume":"386","author":"Thiel","year":"1997","journal-title":"Nature"},{"key":"10.1124\/pharmrev.120.000072_bib370","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.molimm.2017.05.025","article-title":"C1q: a fresh look upon an old molecule","volume":"89","author":"Thielens","year":"2017","journal-title":"Mol Immunol"},{"key":"10.1124\/pharmrev.120.000072_bib371","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1053\/j.ackd.2019.10.003","article-title":"Complement and the kidney: an overview","volume":"27","author":"Thurman","year":"2020","journal-title":"Adv Chronic Kidney Dis"},{"key":"10.1124\/pharmrev.120.000072_bib372","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s10238-019-00565-8","article-title":"Eculizumab in refractory catastrophic antiphospholipid syndrome: a case report and systematic review of the literature","volume":"19","author":"Tinti","year":"2019","journal-title":"Clin Exp Med"},{"key":"10.1124\/pharmrev.120.000072_bib373","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1002\/ajmg.a.30878","article-title":"Michels syndrome, Carnevale syndrome, OSA syndrome, and Malpuech syndrome: variable expression of a single disorder (3MC syndrome)?","volume":"137A","author":"Titomanlio","year":"2005","journal-title":"Am J Med Genet A"},{"key":"10.1124\/pharmrev.120.000072_bib374","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.molimm.2018.06.005","article-title":"Tissue-targeted complement therapeutics","volume":"102","author":"Tomlinson","year":"2018","journal-title":"Mol Immunol"},{"key":"10.1124\/pharmrev.120.000072_bib375","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.molimm.2019.07.017","article-title":"The role of complement in IgA nephropathy","volume":"114","author":"Tortajada","year":"2019","journal-title":"Mol Immunol"},{"key":"10.1124\/pharmrev.120.000072_bib376","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s00467-013-2630-5","article-title":"Use of eculizumab and plasma exchange in successful combined liver-kidney transplantation in a case of atypical HUS associated with complement factor H mutation","volume":"29","author":"Tran","year":"2014","journal-title":"Pediatr Nephrol"},{"key":"10.1124\/pharmrev.120.000072_bib377","first-page":"135","article-title":"C4 binding protein deficiency in a patient with atypical Beh\u00e7et\u2019s disease","volume":"14","author":"Trapp","year":"1987","journal-title":"J Rheumatol"},{"key":"10.1124\/pharmrev.120.000072_bib378","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1111\/cei.13515","article-title":"The rise of complement in ANCA-associated vasculitis: from marginal player to target of modern therapy","volume":"202","author":"Trivioli","year":"2020","journal-title":"Clin Exp Immunol"},{"key":"10.1124\/pharmrev.120.000072_bib379","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.molimm.2009.10.021","article-title":"Double role of mannose-binding lectin in relation to carotid intima-media thickness in patients with rheumatoid arthritis","volume":"47","author":"Troelsen","year":"2010","journal-title":"Mol Immunol"},{"key":"10.1124\/pharmrev.120.000072_bib380","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s10875-019-00627-2","article-title":"Ficolin-3 deficiency is associated with disease and an increased risk of systemic lupus erythematosus","volume":"39","author":"Troldborg","year":"2019","journal-title":"J Clin Immunol"},{"key":"10.1124\/pharmrev.120.000072_bib381","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/j.1442-9071.2011.02581.x","article-title":"Therapeutic targeting of the complement system in age-related macular degeneration: a review","volume":"40","author":"Troutbeck","year":"2012","journal-title":"Clin Exp Ophthalmol"},{"key":"10.1124\/pharmrev.120.000072_bib382","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.molimm.2015.05.007","article-title":"Classical pathway deficiencies - a short analytical review","volume":"68","author":"Truedsson","year":"2015","journal-title":"Mol Immunol"},{"key":"10.1124\/pharmrev.120.000072_bib383","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1007\/s00467-011-1989-4","article-title":"Eculizumab in atypical hemolytic uremic syndrome: long-term clinical course and histological findings","volume":"26","author":"Tschumi","year":"2011","journal-title":"Pediatr Nephrol"},{"key":"10.1124\/pharmrev.120.000072_bib384","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1046\/j.1365-3083.1998.00396.x","article-title":"Reconstitution of opsonizing activity by infusion of mannan-binding lectin (MBL) to MBL-deficient humans","volume":"48","author":"Valdimarsson","year":"1998","journal-title":"Scand J Immunol"},{"key":"10.1124\/pharmrev.120.000072_bib385","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.imbio.2015.11.007","article-title":"Age-related macular degeneration: complement in action","volume":"221","author":"van Lookeren Campagne","year":"2016","journal-title":"Immunobiology"},{"key":"10.1124\/pharmrev.120.000072_bib386","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1038\/nature18283","article-title":"A complement-microglial axis drives synapse loss during virus-induced memory impairment","volume":"534","author":"Vasek","year":"2016","journal-title":"Nature"},{"key":"10.1124\/pharmrev.120.000072_bib387","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0042113","article-title":"Mannose-binding lectin deficiency is associated with myocardial infarction: the HUNT2 study in Norway","volume":"7","author":"Vengen","year":"2012","journal-title":"PLoS One"},{"key":"10.1124\/pharmrev.120.000072_bib388","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/S0041-1345(00)01030-7","article-title":"Relative roles of hCD46 and hCD55 in the regulation of hyperacute rejection","volume":"32","author":"Verbakel","year":"2000","journal-title":"Transplant Proc"},{"key":"10.1124\/pharmrev.120.000072_bib389","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1093\/rheumatology\/kem222","article-title":"Blocking the receptor for C5a in patients with rheumatoid arthritis does not reduce synovial inflammation","volume":"46","author":"Vergunst","year":"2007","journal-title":"Rheumatology (Oxford)"},{"key":"10.1124\/pharmrev.120.000072_bib390","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1172\/JCI107562","article-title":"Glomerular complement components in human glomerulonephritis","volume":"53","author":"Verroust","year":"1974","journal-title":"J Clin Invest"},{"key":"10.1124\/pharmrev.120.000072_bib391","doi-asserted-by":"crossref","first-page":"e764","DOI":"10.1016\/S2665-9913(20)30341-6","article-title":"Anti-C5a antibody IFX-1 (vilobelimab) treatment versus best supportive care for patients with severe COVID-19 (PANAMO): an exploratory, open-label, phase 2 randomised controlled trial","volume":"2","author":"Vlaar","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"10.1124\/pharmrev.120.000072_bib392","doi-asserted-by":"crossref","first-page":"3087","DOI":"10.1016\/j.celrep.2019.11.013","article-title":"The classical complement pathway mediates microglia-dependent remodeling of spinal motor circuits during development and in SMA","volume":"29","author":"Vukojicic","year":"2019","journal-title":"Cell Rep"},{"key":"10.1124\/pharmrev.120.000072_bib393","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1126\/science.aaz2288","article-title":"Microglia mediate forgetting via complement-dependent synaptic elimination","volume":"367","author":"Wang","year":"2020","journal-title":"Science"},{"key":"10.1124\/pharmrev.120.000072_bib394","doi-asserted-by":"crossref","first-page":"10948","DOI":"10.1073\/pnas.1707364114","article-title":"Complement-activation fragment C4a mediates effector functions by binding as untethered agonist to protease-activated receptors 1 and 4","volume":"114","author":"Wang","year":"2017","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/pharmrev.120.000072_bib395","doi-asserted-by":"crossref","DOI":"10.1038\/emi.2015.28","article-title":"The role of C5a in acute lung injury induced by highly pathogenic viral infections","volume":"4","author":"Wang","year":"2015","journal-title":"Emerg Microbes Infect"},{"key":"10.1124\/pharmrev.120.000072_bib396","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/nri1269","article-title":"The dark side of C5a in sepsis","volume":"4","author":"Ward","year":"2004","journal-title":"Nat Rev Immunol"},{"key":"10.1124\/pharmrev.120.000072_bib397","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1126\/science.2371562","article-title":"Soluble human complement receptor type 1: in vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis","volume":"249","author":"Weisman","year":"1990","journal-title":"Science"},{"key":"10.1124\/pharmrev.120.000072_bib398","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.immuni.2019.12.004","article-title":"Targeted complement inhibition at synapses prevents microglial synaptic engulfment and synapse loss in demyelinating disease","volume":"52","author":"Werneburg","year":"2020","journal-title":"Immunity"},{"key":"10.1124\/pharmrev.120.000072_bib399","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/imr.12852","article-title":"Complement and human T cell metabolism: location, location, location","volume":"295","author":"West","year":"2020","journal-title":"Immunol Rev"},{"key":"10.1124\/pharmrev.120.000072_bib400","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s00281-017-0663-8","article-title":"Diseases of complement dysregulation-an overview","volume":"40","author":"Wong","year":"2018","journal-title":"Semin Immunopathol"},{"key":"10.1124\/pharmrev.120.000072_bib401","doi-asserted-by":"crossref","DOI":"10.1111\/eci.13028","article-title":"C5a anaphylatoxin and its role in critical illness-induced organ dysfunction","volume":"48","author":"Wood","year":"2018","journal-title":"Eur J Clin Invest"},{"key":"10.1124\/pharmrev.120.000072_bib402","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1096\/fj.05-5814com","article-title":"Therapeutic activity of C5a receptor antagonists in a rat model of neurodegeneration","volume":"20","author":"Woodruff","year":"2006","journal-title":"FASEB J"},{"key":"10.1124\/pharmrev.120.000072_bib403","doi-asserted-by":"crossref","first-page":"E3","DOI":"10.1073\/pnas.1321248111","article-title":"Role for terminal complement activation in amyotrophic lateral sclerosis disease progression","volume":"111","author":"Woodruff","year":"2014","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/pharmrev.120.000072_bib404","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.2147\/DDDT.S206355","article-title":"Complement system and age-related macular degeneration: drugs and challenges","volume":"13","author":"Wu","year":"2019","journal-title":"Drug Des Devel Ther"},{"key":"10.1124\/pharmrev.120.000072_bib405","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1016\/j.celrep.2019.07.060","article-title":"Complement C3 is activated in human AD brain and is required for neurodegeneration in mouse models of amyloidosis and tauopathy","volume":"28","author":"Wu","year":"2019","journal-title":"Cell Rep"},{"key":"10.1124\/pharmrev.120.000072_bib406","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1046\/j.1365-2249.2000.01263.x","article-title":"Modulation of complement membrane attack by local C7 synthesis","volume":"121","author":"W\u00fcrzner","year":"2000","journal-title":"Clin Exp Immunol"},{"key":"10.1124\/pharmrev.120.000072_bib407","doi-asserted-by":"crossref","first-page":"4624","DOI":"10.4049\/jimmunol.152.9.4624","article-title":"Complement component C7. Assessment of in vivo synthesis after liver transplantation reveals that hepatocytes do not synthesize the majority of human C7","volume":"152","author":"W\u00fcrzner","year":"1994","journal-title":"J Immunol"},{"key":"10.1124\/pharmrev.120.000072_bib408","first-page":"123","article-title":"Inherited deficiencies of the terminal components of human complement","volume":"3","author":"W\u00fcrzner","year":"1992","journal-title":"Immunodefic Rev"},{"key":"10.1124\/pharmrev.120.000072_bib409","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1055\/s-0034-1376334","article-title":"C3 glomerulopathy: the genetic and clinical findings in dense deposit disease and C3 glomerulonephritis","volume":"40","author":"Xiao","year":"2014","journal-title":"Semin Thromb Hemost"},{"key":"10.1124\/pharmrev.120.000072_bib410","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1056\/NEJM199010253231707","article-title":"Inherited complete deficiency of 20-kilodalton homologous restriction factor (CD59) as a cause of paroxysmal nocturnal hemoglobinuria","volume":"323","author":"Yamashina","year":"1990","journal-title":"N Engl J Med"},{"key":"10.1124\/pharmrev.120.000072_bib411","doi-asserted-by":"crossref","first-page":"368","DOI":"10.3389\/fimmu.2012.00368","article-title":"New insights for C5a and C5a receptors in sepsis","volume":"3","author":"Yan","year":"2012","journal-title":"Front Immunol"},{"key":"10.1124\/pharmrev.120.000072_bib412","doi-asserted-by":"crossref","first-page":"724","DOI":"10.3389\/fimmu.2020.00724","article-title":"TLR4 cross-talk with NLRP3 inflammasome and complement signaling pathways in Alzheimer\u2019s disease","volume":"11","author":"Yang","year":"2020","journal-title":"Front Immunol"},{"key":"10.1124\/pharmrev.120.000072_bib413","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1086\/518257","volume":"80","author":"Yang","year":"2007","journal-title":"Am J Hum Genet"},{"key":"10.1124\/pharmrev.120.000072_bib414","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1096\/fj.201601306R","article-title":"Lectin pathway effector enzyme mannan-binding lectin-associated serine protease-2 can activate native complement C3 in absence of C4 and\/or C2","volume":"31","author":"Yaseen","year":"2017","journal-title":"FASEB J"},{"key":"10.1124\/pharmrev.120.000072_bib415","doi-asserted-by":"crossref","first-page":"6481","DOI":"10.1038\/ncomms7481","article-title":"Structural basis for the targeting of complement anaphylatoxin C5a using a mixed L-RNA\/L-DNA aptamer","volume":"6","author":"Yatime","year":"2015","journal-title":"Nat Commun"},{"key":"10.1124\/pharmrev.120.000072_bib416","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.bbapap.2011.05.021","article-title":"Mannose-binding lectin serine proteases and associated proteins of the lectin pathway of complement: two genes, five proteins and many functions?","volume":"1824","author":"Yongqing","year":"2012","journal-title":"Biochim Biophys Acta"},{"key":"10.1124\/pharmrev.120.000072_bib417","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1161\/ATVBAHA.113.303120","article-title":"Complement 5a receptor mediates angiotensin II-induced cardiac inflammation and remodeling","volume":"34","author":"Zhang","year":"2014","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1124\/pharmrev.120.000072_bib418","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1096\/fj.13-242693","article-title":"Sublytic C5b-9 induces IL-6 and TGF-\u03b21 production by glomerular mesangial cells in rat Thy-1 nephritis through p300-mediated C\/EBP\u03b2 acetylation","volume":"28","author":"Zhang","year":"2014","journal-title":"FASEB J"},{"key":"10.1124\/pharmrev.120.000072_bib419","doi-asserted-by":"crossref","first-page":"e60908","DOI":"10.7554\/eLife.60908","article-title":"Soluble collectin-12 mediates C3-independent docking of properdin that activates the alternative pathway of complement","volume":"9","author":"Zhang","year":"2020","journal-title":"eLife"},{"key":"10.1124\/pharmrev.120.000072_bib420","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.yjmcc.2006.02.006","article-title":"The role of natural IgM in myocardial ischemia-reperfusion injury","volume":"41","author":"Zhang","year":"2006","journal-title":"J Mol Cell Cardiol"},{"key":"10.1124\/pharmrev.120.000072_bib421","doi-asserted-by":"crossref","first-page":"4727","DOI":"10.4049\/jimmunol.177.7.4727","article-title":"Activation of the lectin pathway by natural IgM in a model of ischemia\/reperfusion injury","volume":"177","author":"Zhang","year":"2006","journal-title":"J Immunol"},{"key":"10.1124\/pharmrev.120.000072_bib422","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1261\/rna.073536.119","article-title":"eIF1 discriminates against suboptimal initiation sites to prevent excessive uORF translation genome-wide","volume":"26","author":"Zhou","year":"2020","journal-title":"RNA"},{"key":"10.1124\/pharmrev.120.000072_bib423","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.4049\/jimmunol.128.6.2500","article-title":"Spontaneous activation of the first component of human complement (C1) by an intramolecular autocatalytic mechanism","volume":"128","author":"Ziccardi","year":"1982","journal-title":"J Immunol"}],"container-title":["Pharmacological Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031699724006628?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031699724006628?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/pharmrev.120.000072","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T12:34:07Z","timestamp":1740746047000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0031699724006628"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":423,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["S0031699724006628"],"URL":"https:\/\/doi.org\/10.1124\/pharmrev.120.000072","relation":{},"ISSN":["0031-6997"],"issn-type":[{"value":"0031-6997","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic Targeting of the Complement System: From Rare Diseases to Pandemics","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/pharmrev.120.000072","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 by The Author(s)","name":"copyright","label":"Copyright"}]}}